[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"Fresenius Kabi USA, LLC\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":116},{"warningLetters":4,"total":115},[5,32,55,78,98],{"id":6,"raw":7,"subject":12,"body_html":14,"body_text":15,"firm_name":16,"letter_id":17,"created_at":18,"fei_number":19,"letter_url":20,"updated_at":21,"action_type":22,"case_status":23,"posted_date":24,"marcs_cms_no":25,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":27,"body_fetched_at":28,"delivery_method":29,"recipient_title":19,"reference_number":30,"action_taken_date":31,"medical_device_id":19,"response_letter_date":19},21720,[8,9,10,11,12,13,13,13],"\u003Ctime datetime=\"2026-09-29T04:00:00Z\">09\u002F29\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-09-22T04:00:00Z\">09\u002F22\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ffresenius-kabi-usa-llc-733107-09222026\"> Fresenius Kabi USA LLC\u003C\u002Fa>","Center for Drug Evaluation and Research (CDER)","CGMP\u002FFinished Pharmaceuticals\u002FAdulterated","","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-26-129\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Pierluigi Antonelli\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd> Fresenius Kabi USA LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>61346\u003C\u002Fspan> \u003Cspan>Bad Homburg\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Germany\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:(b)(4)\"> (b)(4)\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>September 22, 2026\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>Reference number: 320-26-129\u003C\u002Fp>\u003Cp>To Mr. Antonelli:\u003C\u002Fp>\u003Cp>This warning letter advises you of significant violations observed during a U.S. Food and Drug Administration (FDA) inspection of your facility. Promptly address the violations described herein without delay, including ensuring that appropriate resources are allocated to fully address the violations and prevent their recurrence. This is not intended to be an all-inclusive list of the violations that exist at your facility. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address violations may result in regulatory or legal action without further notice including, without limitation, seizure and injunction.\u003C\u002Fp>\u003Cp>\u003Cstrong>FDA Inspection\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Violations were observed and documented during an inspection of your drug manufacturing facility, Fresenius Kabi USA LLC, FDA Establishment Identifier (FEI) 1450022, at 2085 N Hawthorne Ave, Melrose Park, IL from January 27 to February 18, 2026. This inspection was conducted under FDA’s statutory authority and public health responsibilities to protect the public from unsafe, ineffective, and poor quality drugs.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>We reviewed your March 11, 2026, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\u003C\u002Fp>\u003Cp>\u003Cstrong>Violations of the Federal Food, Drug, and Cosmetic Act\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The following are violations identified during our inspection and review. As a reminder, this is not an all-inclusive list of violations at your facility.\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm is a manufacturer of sterile injectable drug products produced primarily through aseptic processing, including but not limited to, products for intravenous \u003Cstrong>(b)(4)\u003C\u002Fstrong> use. You failed to adequately investigate drug product failures and discrepancies.\u003C\u002Fp>\u003Cp>Your investigations lacked data-supported root causes, formal documentation, expansion to all potentially affected products, and corrective action effectiveness checks. In multiple investigations, you inappropriately concluded there was no product impact based on overreliance on passing finished drug product test results (e.g., sterility, endotoxin, and environmental monitoring). The following examples illustrate these failures:\u003C\u002Fp>\u003Cp>\u003Cem>Endotoxin Test Failures\u003C\u002Fem>\u003C\u002Fp>\u003Cp>In 2025 and 2026, your firm received reports of patients experiencing adverse drug events, including apparent pyrogenic reactions, following administration of famotidine for injection. Notably, famotidine injection manufacturing had experienced multiple \u003Cstrong>(b)(4)\u003C\u002Fstrong> bioburden action limit failures. However, your firm failed to sufficiently investigate this critical deviation and permitted batch release following passing finished drug product test results (i.e., sterility, endotoxin).\u003C\u002Fp>\u003Cp>Subsequent testing of finished product retains, as part of the investigation into the adverse event complaints, revealed an endotoxin failure. Your firm ultimately recalled three famotidine injection batches.\u003C\u002Fp>\u003Cp>Your response acknowledges that \u003Cstrong>(b)(4)\u003C\u002Fstrong> bioburden samples showed gram-negative confluent growth. You state that, at the time of disposition of the affected batches, your firm did not consider the excessive bioburden to constitute an elevated endotoxin risk. You commit to revising procedures to ensure enhanced endotoxin sampling and testing whenever action-level gram-negative bacteria are identified during \u003Cstrong>(b)(4)\u003C\u002Fstrong> bioburden testing.\u003C\u002Fp>\u003Cp>Your response is inadequate. You do not commit to comprehensive review and CAPA of your complaint system to increase vigilance, or to extensive CAPA effectiveness checks.\u003C\u002Fp>\u003Cp>In order to prevent parenteral drug contamination with pyrogenic substances, including endotoxins, it is critical that your firm build quality into manufacturing operations and maintain ongoing robust upstream control. It should be noted that endotoxins are not retained by \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Any batch testing that reveals atypical bioburden levels is a signal that necessitates prompt attention. Pyrogen contamination in parenteral drug products can lead to significant adverse events such as fever, hypotension, inflammatory reactions, anaphylactic shock or death.\u003C\u002Fp>\u003Cp>For more information about pyrogen and endotoxin testing, see FDA’s \u003Cem>Guidance for Industry Pyrogen and Endotoxins Testing: Questions and Answers\u003C\u002Fem> https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F83477\u002Fdownload.\u003C\u002Fp>\u003Cp>\u003Cem>Media Fill Failures\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Your firm experienced media fill failures on your aseptic manufacturing Line \u003Cstrong>(b)(4)\u003C\u002Fstrong> with limited barrier protection in September and October 2024. Media fill failures also occurred on \u003Cstrong>(b)(4)\u003C\u002Fstrong> Restricted Access Barrier System manufacturing Line \u003Cstrong>(b)(4)\u003C\u002Fstrong> in April and October 2025. In each case, you determined the most probable contributing factors for each failure were deficient aseptic techniques by your operators. Your investigations did not consider how the poor aseptic practices went undetected by your firm’s aseptic observer program during commercial operations.\u003C\u002Fp>\u003Cp>Your response includes your ongoing effort to improve aseptic practices, especially on your aseptic processing lines with limited barrier protection. You commit to an aseptic operations program assessment, updating procedures, and training operators.\u003C\u002Fp>\u003Cp>Your response is inadequate because it does not provide clear timelines for addressing the fundamental design flaws of your aseptic processing lines with limited barrier protection which are inherently vulnerable to excessive contamination risk. Following your media fill failures, you placed \u003Cstrong>(b)(4)\u003C\u002Fstrong> commercial batches on hold, however, you did not act similarly for liquid products produced on your \u003Cstrong>(b)(4)\u003C\u002Fstrong> aseptic manufacturing lines with limited barrier protection. Notably, those processing lines shared operators from the processing lines associated with deficient aseptic techniques and media fill failures.\u003C\u002Fp>\u003Cp>\u003Cem>Extrinsic Biological Contamination (e.g., hair)\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Beginning in May 2022, you documented at least nine incidences of extrinsic contamination (e.g., hair) during your visible particulate inspection. This contamination was described as free-floating and in direct contact with the drug product. Drug products contaminated with hair can have microbial contamination and are generally considered adulterated. You did not initiate timely investigations in response to this contamination.\u003C\u002Fp>\u003Cp>Your response acknowledges the significance of issues involving extrinsic biological particulates and recognizes a procedural gap in how you classified critical defects such as extrinsic biological contamination. You commit to continuous improvement of your investigations program. Additionally, you commit to revising your particulate management system, conducting targeted supplier audits, and discontinuing tailgate samples for incoming stopper lots.\u003C\u002Fp>\u003Cp>Your response is inadequate. You did not address why your quality unit (QU), your Corporate Expert Circle, and your Corporate Emergency Committee did not reject commercial batches associated with the extrinsic biological contamination and instead released them for distribution to your customers. Also, you did not provide details of your heightened incoming quality control of stoppers. Additionally, your response does not indicate that you examined retains of your distributed drug products for the presence of hair.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, out-of-specification results, out-of-limit results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, the following:\u003Cbr>o Significant improvements in investigation competencies\u003Cbr>o Root cause evaluation and scope determination\u003Cbr>o Corrective action and preventive action (CAPA) effectiveness\u003Cbr>o Quality assurance unit oversight, and written procedures\u003Cbr>o Address how your firm will ensure all phases of investigations are appropriately conducted.\u003C\u002Fli>\u003Cli>A comprehensive review of root cause investigations for deviations related to biological particulate matter found in your products, including incoming inspection activities and subsequent CAPA activities. Provide supporting documents, including data generated and effectiveness evaluations.\u003C\u002Fli>\u003Cli>An independent, retrospective review of all critical investigations (including each in-process, release, and stability test specification failure) for the last three years as of the date of this letter. Evaluate the adequacy of each investigation, including but not limited to, the following:\u003Cbr>o Determine whether a thorough review of production (e.g., batch manufacturing records, adequacy of the manufacturing steps, suitability of equipment\u002Ffacilities, variability of raw materials, process capability, deviation history, complaint history, batch failure history) was conducted.\u003Cbr>o Assess sufficiency of review of related data and investigations to identify if there are potential systemic linkages.\u003Cbr>o Evaluate adequacy of scope, rigor, staff competencies, scientific\u002Fanalytical foundation, root cause determinations, and CAPA.\u003Cbr>o Summary of findings of the assessment for each of the above elements.\u003C\u002Fli>\u003Cli>An independent assessment and remediation plan for your CAPA program. Provide a report that evaluates whether the program includes effective root cause analysis, ensures CAPA effectiveness, analyzes investigations trends, improves the CAPA program whenever needed, ensures final quality assurance unit decision authority, and is fully supported by executive management.\u003C\u002Fli>\u003Cli>A comprehensive evaluation of your program to prevent endotoxin contamination risks and associated CAPA, including but not limited to:\u003Cbr>o Containers and Closures (\u003Cstrong>(b)(4)\u003C\u002Fstrong> packaging components)\u003Cbr>o Ingredients\u003Cbr>o \u003Cstrong>(b)(4)\u003C\u002Fstrong> systems\u003Cbr>o Process and procedural controls\u003Cbr>o Design and control of your equipment, including preventive maintenance and repairs\u003Cbr>o Manufacturing environment\u003C\u002Fli>\u003Cli>An independent, comprehensive review of your environmental monitoring (EM) program to ensure vigilant, timely detection and response to potential product contamination hazards in your manufacturing environment. This assessment should include, but not be limited to, the following:\u003Cbr>o Establishing appropriate limits\u003Cbr>o Sampling methods\u003Cbr>o Sampling locations and frequencies\u003Cbr>o Trend analysis\u003Cbr>o Appropriate investigation of deviations and adverse trends\u003Cbr>o Comprehensive CAPA plan based on the findings of the assessment\u003C\u002Fli>\u003Cli>A comprehensive, independent review of your process simulation (e.g., media fill) program to ensure accurate simulations of commercial aseptic manufacturing operations, including but not limited to appropriate incorporation of worst-case conditions.\u003C\u002Fli>\u003Cli>An independent assessment of vials rejected for hair contamination, and an update that summarizes all analyses performed on suspected foreign matter identified as part of batch production (within expiration date) or after testing retains related to complaints.\u003C\u002Fli>\u003Cli>The most updated status on your supplier quality investigations for stoppers and any remediation efforts. Include the following:\u003Cbr>o Incoming component inspection results\u003Cbr>o Defect trends and Acceptable Quality Limit performance\u003Cbr>o Whether biological particulates have been identified in any incoming \u003Cstrong>(b)(4)\u003C\u002Fstrong> packaging components in the last three years\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>2. Your firm failed to establish and follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile, and that include validation of all aseptic and sterilization processes (21 CFR 211.113(b)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cem>Inadequate Aseptic Process Simulations (Media Fills)\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Your media fills failed to accurately simulate aseptic manufacturing operations.\u003C\u002Fp>\u003Cp>At the time of the inspection, your firm used a sampling approach to determine a representative number of each intervention necessary to simulate your aseptic processes. A review showed that your media fill simulations did not adequately represent your maximum aseptic intervention counts (e.g., clearing stoppers in the \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u002Ftrack, \u003Cstrong>(b)(4)\u003C\u002Fstrong> application, \u003Cstrong>(b)(4)\u003C\u002Fstrong> adjustment, removing vials from the \u003Cstrong>(b)(4)\u003C\u002Fstrong>). Additionally, inherent interventions (e.g., stopper additions, vial loading) are not documented in your batch records, which has the consequence of inadequate assessment of the risks these interventions present during actual aseptic production. Also, data indicated that the number of units in your media fills was insufficient.\u003C\u002Fp>\u003Cp>Inadequate documentation of interventions was the subject of findings from FDA’s 2022 inspection.\u003C\u002Fp>\u003Cp>In your response, you acknowledge some interventions did not simulate the maximum risk to your aseptic processes. You commit to implement an intervention docking and tracking system and enhanced oversight of related data. You state that you will ensure thorough review of batch intervention data in the future to support simulation of inherent and corrective interventions using an appropriate worst-case approach.\u003C\u002Fp>\u003Cp>Your response is inadequate. We acknowledge your commitment to conduct appropriate media fill simulations for your aseptic processing lines. However, you do not address the need for sufficient media fill batch sizes and your response lacks sufficient detail on how you will document and track interventions.\u003C\u002Fp>\u003Cp>When the potential for contamination is higher, as it is with your \u003Cstrong>(b)(4)\u003C\u002Fstrong> processing lines surrounded by barrier \u003Cstrong>(b)(4)\u003C\u002Fstrong>, the number of units in a media fill should be the same as, or approach, the maximum production batch size. If a media fill program fails to incorporate contamination risk factors and closely simulate actual drug product exposure, the state of process control and assurance of sterility cannot be accurately assessed. Furthermore, your \u003Cstrong>(b)(4)\u003C\u002Fstrong> aseptic processing lines require an inordinate number of interventions and there is a need for fundamental design remediations. Notably, media fills cannot justify unsuitable manufacturing lines and processing conditions.\u003C\u002Fp>\u003Cp>\u003Cem>Aseptic Technique and Poor Cleanroom Behavior\u003C\u002Fem>\u003C\u002Fp>\u003Cp>We observed poor aseptic practices and inadequate oversight. These deviations included, but were not limited to, the following:\u003C\u002Fp>\u003Cul>\u003Cli>Operators opening and closing \u003Cstrong>(b)(4)\u003C\u002Fstrong> doors with sharp movements while performing \u003Cstrong>(b)(4)\u003C\u002Fstrong> aseptic loading of \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fli>\u003Cli>Operators repeatedly contacted the \u003Cstrong>(b)(4)\u003C\u002Fstrong> barrier \u003Cstrong>(b)(4)\u003C\u002Fstrong> with their head and upper torso, including during \u003Cstrong>(b)(4)\u003C\u002Fstrong> installation and \u003Cstrong>(b)(4)\u003C\u002Fstrong> set up.\u003C\u002Fli>\u003Cli>Operators \u003Cstrong>(b)(4)\u003C\u002Fstrong> clamps over the \u003Cstrong>(b)(4)\u003C\u002Fstrong> sterile end of tubing (which conveys the sterile formulation) during setup activities.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>In your response, you discuss your ongoing efforts to improve your aseptic operations, and you commit to engaging a third-party consultant to assess your aseptic operation oversight. Also, you commit to implementing a standardized interview template when investigations involving personnel activities or interventions relate to human error. Additionally, you commit to improving classified area material handling.\u003C\u002Fp>\u003Cp>Your response fails to sufficiently acknowledge design flaws including, but not limited to, inadequate processing line layout, ergonomic deficiencies, excessive need for \u003Cstrong>(b)(4)\u003C\u002Fstrong> manipulations, insufficient barrier protection to provide adequate separation from surrounding areas, and other fundamental issues.\u003C\u002Fp>\u003Cp>The ISO 5 (Grade A) area is critical because sterile products are exposed during aseptic production and therefore vulnerable to contamination if operations are not well designed and diligently controlled. Your aseptic processes should be designed, and operations executed, to prevent contamination hazards to your sterile product. Flaws in the design of cleanrooms and aseptic processing lines, or improper execution of operations, can promote an influx of contamination into the critical processing area.\u003C\u002Fp>\u003Cp>See FDA’s guidance document \u003Cem>Sterile Drug Products Produced by Aseptic Processing – Current Good Manufacturing Practice\u003C\u002Fem> to help you meet the CGMP requirements when manufacturing sterile drugs using aseptic processing at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71026\u002Fdownload.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive, independent risk assessment of all contamination hazards with respect to your aseptic processes, equipment, and facilities, including but not limited to, the following:\u003Cbr>o All human interactions within the ISO 5 area (e.g., risk reduction or elimination of \u003Cstrong>(b)(4)\u003C\u002Fstrong> interventions wherever possible)\u003Cbr>o Equipment suitability (e.g., reliability, capability, ergonomics, placement) and sufficient cleanroom space\u003Cbr>o Air quality in the ISO 5 area and surrounding room including, but not limited to, air volume and flow\u003Cbr>o Facility layout\u003Cbr>o Personnel flow and material flow (movement throughout all rooms used to conduct and support sterile operations and all material transfers)\u003Cbr>o Disinfection practices and procedures\u003Cbr>o Specific CAPA recommendations that will comprehensively address the design and control hazards identified in the risk assessment\u003Cbr>o A detailed remediation plan with timelines to address the findings of the contamination hazards risk assessment. Describe specific tangible, comprehensive improvements to be made to aseptic processing operation design and control of your \u003Cstrong>(b)(4)\u003C\u002Fstrong> processing lines surrounded by barrier \u003Cstrong>(b)(4)\u003C\u002Fstrong> and explain how this CAPA plan will thoroughly and robustly remediate your deficient \u003Cstrong>(b)(4)\u003C\u002Fstrong> aseptic processing lines.\u003C\u002Fli>\u003Cli>Your systematic plan to assure adherence to appropriate aseptic practices, cleanroom behavior, and written procedures, including but not limited to, an independent assessment of the following with accompanying CAPA:\u003Cbr>o Suitability of actual practices based on extensive retrospective review and prospective observation of aseptic processing operations\u003Cbr>o Deficiencies in production management oversight, and identification of specific improvements to ensure effective and routine supervisory oversight for all batches\u003Cbr>o Frequency and depth of quality unit oversight (e.g., audit, ad hoc, daily interactions) of aseptic processing and its support operations\u003Cbr>o Adequacy of written procedures and operational ergonomics\u003Cbr>The assessment should also evaluate how poor aseptic technique and cleanroom behavior may have affected the quality and sterility of your drugs.\u003C\u002Fli>\u003Cli>In an easily searchable tabular format, your updated plan to expedite the transfer of manufacturing from your Building \u003Cstrong>(b)(4)\u003C\u002Fstrong> aseptic filling lines to your Building \u003Cstrong>(b)(4)\u003C\u002Fstrong> lines without creating drug shortages. Include a list of backup contract manufacturing organizations that would be utilized in the event you are unable to ensure supply chain continuity.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>3. Your firm failed to establish adequate control procedures to monitor the output and to validate the performance of those manufacturing processes that may be responsible for causing variability in the characteristics of in-process material and the drug. Your firm failed to perform operations within specifically defined areas of adequate size and to have separate or defined areas or such other control systems necessary to prevent contamination or mix-ups in aseptic processing areas (21 CFR 211.110(a) and 21 CFR 211.42(c)(10)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cem>Inadequate Visual Inspection Program\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Your visual inspection program is inadequate to ensure your sterile injectable drug products are essentially free of visible particulates and defects. For example:\u003C\u002Fp>\u003Cul>\u003Cli>You categorized all non-glass particulate, regardless of material type (i.e., hair) as major, which means more severe particulates of biological origin are not considered critical.\u003C\u002Fli>\u003Cli>\u003Cstrong>(b)(4)\u003C\u002Fstrong> visible particulate inspection systems often exhibited low detectability and high variability regardless of particle type (e.g., glass, white particulate, black particulate) and size.\u003C\u002Fli>\u003Cli>Your probability of detection (POD) of particulates using \u003Cstrong>(b)(4)\u003C\u002Fstrong> visual inspection was inadequate. Your methods often exhibit PODs significantly less than \u003Cstrong>(b)(4)\u003C\u002Fstrong>% for particulate matter defects. In addition, glass particulates in the visible range were not consistently detected.\u003C\u002Fli>\u003Cli>You lacked defect limits for specific types of non-glass particulate matter in the visual inspection program.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>In your response, you recognize that studies did not generate sufficient data across increasing particulate sizes to adequately qualify your visual inspection program and that comparison reports were not completed. Additionally, you indicated that all extrinsic particulates are now classified as critical defects and acknowledge the potential loss of sterility often associated with such particulates.\u003C\u002Fp>\u003Cp>Your response is inadequate. Although you commit to evaluating the visual inspection program with the assistance of an independent third-party consultant, your response lacks a sufficient assessment of products currently on the market.\u003C\u002Fp>\u003Cp>Visual detection of particulates is a probabilistic process that depends on, among other things, ensuring that visible particulates can be reproducibly detected by highly capable systems including, but not limited to, trained personnel with appropriate visual acuity. At a minimum, your visual inspection systems should reliably be capable of detecting particulates of 150 microns or greater at a 70% probability of detection. Furthermore, written procedures governing 100% inspections for visual particulates should clearly define the number of times re-inspection may be performed. You should limit and justify re-inspections. Generally, FDA does not recommend more than one re-inspection in an attempt to release a batch with atypical defect levels\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>.\u003C\u002Fp>\u003Cp>\u003Cem>Inadequate Design of Facility and Equipment\u003C\u002Fem>\u003C\u002Fp>\u003Cp>We observed your \u003Cstrong>(b)(4)\u003C\u002Fstrong> processing lines \u003Cstrong>(b)(4)\u003C\u002Fstrong> surrounded by barrier \u003Cstrong>(b)(4)\u003C\u002Fstrong> under ceiling-fed high efficiency particulate air (HEPA) systems. These processing lines required frequent \u003Cstrong>(b)(4)\u003C\u002Fstrong> activities during equipment setup and throughout routine production and did not provide appropriate separation and protection of the ISO 5 areas. For example, we observed the following regarding these aseptic processing lines:\u003C\u002Fp>\u003Cul>\u003Cli>The use of \u003Cstrong>(b)(4)\u003C\u002Fstrong> tubing, \u003Cstrong>(b)(4)\u003C\u002Fstrong> clamps, and hand tools when making critical aseptic connections within the ISO 5 area that risk interruption of first-pass air and introduce contamination hazards\u003C\u002Fli>\u003Cli>The use of barrier \u003Cstrong>(b)(4)\u003C\u002Fstrong> of varying lengths across each line, which provided inadequate protection of the ISO 5 processing line\u003C\u002Fli>\u003Cli>Frequent high-risk corrective interventions\u003C\u002Fli>\u003C\u002Ful>\u003Cp>In your response, you emphasize that your firm has been focused on your plan to transition production from your current aseptic manufacturing lines \u003Cstrong>(b)(4)\u003C\u002Fstrong> to your \u003Cstrong>(b)(4)\u003C\u002Fstrong> lines rather than updating the sterility assurance controls on your original lines. You further commit to re-evaluating and improving your aseptic processing lines with the assistance of a third-party.\u003C\u002Fp>\u003Cp>Your response is inadequate. Your response lacks sufficient detail and corrective actions for sterility assurance improvements while you continue to use your \u003Cstrong>(b)(4)\u003C\u002Fstrong> processing lines with their inherent design flaws.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive, independent assessment and remediation plan for your visual inspection program to ensure compliance with CGMP. The assessment and remediation should include, but not be limited to, the following:\u003Cbr>o Implementing enhancements to your 100% visible inspection program, including defining critical, major, and minor defects and the individual defect limits for drug products.\u003Cbr>o Ensuring adequate methods, equipment, and personnel qualifications to reproducibly detect visible particulates, including particulates which historically have been identified in your operation.\u003Cbr>o Conducting rigorous qualification studies to ensure your \u003Cstrong>(b)(4)\u003C\u002Fstrong> visible particulate inspection systems consistently and reproducibly detects the variety of visible particulates encountered in your drug products.\u003Cbr>o For drug products that are difficult to inspect (e.g., \u003Cstrong>(b)(4)\u003C\u002Fstrong> containers), implementing destructive testing or other advanced technologies (e.g., \u003Cstrong>(b)(4)\u003C\u002Fstrong>) as appropriate, with statistically significant sample sizes to test for defects.\u003Cbr>o Incorporating product-specific knowledge, process experience, deviation investigation analysis, recall\u002Fcomplaint data, and quality risk management to improve the visual inspection program.\u003C\u002Fli>\u003Cli>Your associated remediations to your visual inspection program, including any newly established written procedures, equipment, and methods. Include a summary of the review and recommendations made by your independent consultant.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>Visible Particulate Contamination\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>We encourage the use of suitable \u003Cstrong>(b)(4)\u003C\u002Fstrong> visual inspection for particulates to augment the \u003Cstrong>(b)(4)\u003C\u002Fstrong> visual inspection program. \u003Cstrong>(b)(4)\u003C\u002Fstrong> methods should be rigorously studied, and qualified, to assess their capability and robustness under various conditions, machine settings, container-closure sizes, defect types, product characteristic, and other variables. In addition, any use of \u003Cstrong>(b)(4)\u003C\u002Fstrong> particulate inspection as an adjunct method does not supplant the need for \u003Cstrong>(b)(4)\u003C\u002Fstrong> visual inspection for various other attributes (e.g., cracks; myriad defects of container or closure; \u003Cstrong>(b)(4)\u003C\u002Fstrong> issues, volume, atypical, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, or other appearance defects).\u003C\u002Fp>\u003Cp>\u003Cstrong>Quality Systems\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm’s quality systems are inadequate. For guidance on establishing and maintaining CGMP-compliant quality systems, see FDA guidance documents: \u003Cem>Q8(R2) Pharmaceutical Development\u003C\u002Fem> at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71535\u002Fdownload,\u003Cbr>\u003Cem>Q9(R1) Quality Risk Management\u003C\u002Fem> at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F167721\u002Fdownload, and \u003Cem>Q10 Pharmaceutical Quality System\u003C\u002Fem> at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71553\u002Fdownload.\u003C\u002Fp>\u003Cp>\u003Cstrong>CGMP Consultant\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based upon the nature of the violations we identified at your firm and because you failed to correct repeat violations, you should engage a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements.\u003C\u002Fp>\u003Cp>Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\u003Cp>\u003Cstrong>Recall Discussion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>On July 9, 2026, FDA held a teleconference with your firm to discuss voluntary recall. During this call, FDA informed you that our inspection revealed that drug products produced at Fresenius Kabi USA LLC contain particulate of biological origin, do not meet CGMP requirements, and are considered adulterated. Your firm initially released these adulterated batches for distribution based on your assertion that product testing results were adequate. Following the recall discussion with FDA, your firm committed to recalling six batches of drug products. As a result, on July 16, 2026, recalls were initiated for:\u003C\u002Fp>\u003Cul>\u003Cli>Glycopyrrolate Injection, USP\u003C\u002Fli>\u003Cli>Lidocaine HCl Injection, USP\u003C\u002Fli>\u003Cli>Ropivacaine Hydrocholoride Injection, USP\u003C\u002Fli>\u003Cli>Lidocaine HCl Injection, USP\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>Request for a Meeting with FDA\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>After you submit your response to this warning letter, we recommend you reach out to this office to arrange for a teleconference to discuss your corrective and preventive actions in detail. Please direct your request to Christina Reyes at christina.reyes@fda.hhs.gov and cc: CDER-OC-OMQ-Communications@fda.hhs.gov.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You are responsible for investigating and determining the root causes of any violations and implementing corrective and preventative measures to ensure future and sustained compliance so that these violations and any others do not occur.\u003C\u002Fp>\u003Cp>Unresolved violations may prevent other Federal agencies from awarding contracts. Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\u003Cp>If you are considering an action that is likely to lead to a disruption in the supply of drugs produced at your facility, FDA requests that you contact CDER’s Drug Shortages Staff immediately, at drugshortages@fda.hhs.gov, so that FDA can work with you on the most effective way to bring your operations into compliance with the law. Contacting the Drug Shortages Staff also allows you to meet any obligations you may have to report discontinuances or interruptions in your drug manufacture under 21 U.S.C. 356c(b). This also allows FDA to consider, as soon as possible, what actions, if any, may be needed to avoid shortages and protect the health of patients who depend on your products.\u003C\u002Fp>\u003Cp>Send your written response to CDER-OC-OMQ-Communications@fda.hhs.gov within fifteen (15) business days of receipt of this letter\u003Cem>\u003Cstrong>\u003Csup>2\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>. Identify your written response with FEI 1450022 and ATTN: Carrie A. Hughes in the subject line of the email.\u003C\u002Fp>\u003Cp>If you have information that you believe demonstrates that your products are not in violation of the FD&amp;C Act and FDA regulations, include that information for our consideration.\u003C\u002Fp>\u003Cp>Please note FDA posts warning letters on www.FDA.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>U.S. Food and Drug Administration\u003C\u002Fp>\u003Cp>cc: Mr. Steven R. Nowicki\u003Cbr>Plant Manager, Fresenius Kabi USA LLC\u003Cbr>Melrose Park, IL\u003Cbr>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>_________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> See FDA’s draft guidance document Inspection of Injectable Products for Visible Particulates to help you meet the CGMP requirements pertaining to visible particulate inspections of sterile injectable drug products at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F154868\u002Fdownload.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> Under program enhancements for the Generic Drug User Fee Amendments (GDUFA) reauthorization for fiscal years (FYs) 2023-2027, also known as the GDUFA III Commitment Letter, your facility may be eligible for a Post-Warning Letter Meeting to obtain preliminary feedback from FDA on the adequacy and completeness of your corrective action plans.\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n\nReference #:\n\n320-26-129\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Pierluigi Antonelli\n\nRecipient Title\n\nChief Executive Officer\n\nFresenius Kabi USA LLC\n\n61346 Bad Homburg\n\nGermany\n\n(b)(4)\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nSeptember 22, 2026\nWARNING LETTER\nReference number: 320-26-129\nTo Mr. Antonelli:\nThis warning letter advises you of significant violations observed during a U.S. Food and Drug Administration (FDA) inspection of your facility. Promptly address the violations described herein without delay, including ensuring that appropriate resources are allocated to fully address the violations and prevent their recurrence. This is not intended to be an all-inclusive list of the violations that exist at your facility. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address violations may result in regulatory or legal action without further notice including, without limitation, seizure and injunction.\nFDA Inspection\nViolations were observed and documented during an inspection of your drug manufacturing facility, Fresenius Kabi USA LLC, FDA Establishment Identifier (FEI) 1450022, at 2085 N Hawthorne Ave, Melrose Park, IL from January 27 to February 18, 2026. This inspection was conducted under FDA’s statutory authority and public health responsibilities to protect the public from unsafe, ineffective, and poor quality drugs.\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\nWe reviewed your March 11, 2026, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\nViolations of the Federal Food, Drug, and Cosmetic Act\nThe following are violations identified during our inspection and review. As a reminder, this is not an all-inclusive list of violations at your facility.\n1. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\nYour firm is a manufacturer of sterile injectable drug products produced primarily through aseptic processing, including but not limited to, products for intravenous (b)(4) use. You failed to adequately investigate drug product failures and discrepancies.\nYour investigations lacked data-supported root causes, formal documentation, expansion to all potentially affected products, and corrective action effectiveness checks. In multiple investigations, you inappropriately concluded there was no product impact based on overreliance on passing finished drug product test results (e.g., sterility, endotoxin, and environmental monitoring). The following examples illustrate these failures:\nEndotoxin Test Failures\nIn 2025 and 2026, your firm received reports of patients experiencing adverse drug events, including apparent pyrogenic reactions, following administration of famotidine for injection. Notably, famotidine injection manufacturing had experienced multiple (b)(4) bioburden action limit failures. However, your firm failed to sufficiently investigate this critical deviation and permitted batch release following passing finished drug product test results (i.e., sterility, endotoxin).\nSubsequent testing of finished product retains, as part of the investigation into the adverse event complaints, revealed an endotoxin failure. Your firm ultimately recalled three famotidine injection batches.\nYour response acknowledges that (b)(4) bioburden samples showed gram-negative confluent growth. You state that, at the time of disposition of the affected batches, your firm did not consider the excessive bioburden to constitute an elevated endotoxin risk. You commit to revising procedures to ensure enhanced endotoxin sampling and testing whenever action-level gram-negative bacteria are identified during (b)(4) bioburden testing.\nYour response is inadequate. You do not commit to comprehensive review and CAPA of your complaint system to increase vigilance, or to extensive CAPA effectiveness checks.\nIn order to prevent parenteral drug contamination with pyrogenic substances, including endotoxins, it is critical that your firm build quality into manufacturing operations and maintain ongoing robust upstream control. It should be noted that endotoxins are not retained by (b)(4). Any batch testing that reveals atypical bioburden levels is a signal that necessitates prompt attention. Pyrogen contamination in parenteral drug products can lead to significant adverse events such as fever, hypotension, inflammatory reactions, anaphylactic shock or death.\nFor more information about pyrogen and endotoxin testing, see FDA’s Guidance for Industry Pyrogen and Endotoxins Testing: Questions and Answers https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F83477\u002Fdownload.\nMedia Fill Failures\nYour firm experienced media fill failures on your aseptic manufacturing Line (b)(4) with limited barrier protection in September and October 2024. Media fill failures also occurred on (b)(4) Restricted Access Barrier System manufacturing Line (b)(4) in April and October 2025. In each case, you determined the most probable contributing factors for each failure were deficient aseptic techniques by your operators. Your investigations did not consider how the poor aseptic practices went undetected by your firm’s aseptic observer program during commercial operations.\nYour response includes your ongoing effort to improve aseptic practices, especially on your aseptic processing lines with limited barrier protection. You commit to an aseptic operations program assessment, updating procedures, and training operators.\nYour response is inadequate because it does not provide clear timelines for addressing the fundamental design flaws of your aseptic processing lines with limited barrier protection which are inherently vulnerable to excessive contamination risk. Following your media fill failures, you placed (b)(4) commercial batches on hold, however, you did not act similarly for liquid products produced on your (b)(4) aseptic manufacturing lines with limited barrier protection. Notably, those processing lines shared operators from the processing lines associated with deficient aseptic techniques and media fill failures.\nExtrinsic Biological Contamination (e.g., hair)\nBeginning in May 2022, you documented at least nine incidences of extrinsic contamination (e.g., hair) during your visible particulate inspection. This contamination was described as free-floating and in direct contact with the drug product. Drug products contaminated with hair can have microbial contamination and are generally considered adulterated. You did not initiate timely investigations in response to this contamination.\nYour response acknowledges the significance of issues involving extrinsic biological particulates and recognizes a procedural gap in how you classified critical defects such as extrinsic biological contamination. You commit to continuous improvement of your investigations program. Additionally, you commit to revising your particulate management system, conducting targeted supplier audits, and discontinuing tailgate samples for incoming stopper lots.\nYour response is inadequate. You did not address why your quality unit (QU), your Corporate Expert Circle, and your Corporate Emergency Committee did not reject commercial batches associated with the extrinsic biological contamination and instead released them for distribution to your customers. Also, you did not provide details of your heightened incoming quality control of stoppers. Additionally, your response does not indicate that you examined retains of your distributed drug products for the presence of hair.\nIn response to this letter, provide:\nA comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, out-of-specification results, out-of-limit results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, the following:\no Significant improvements in investigation competencies\no Root cause evaluation and scope determination\no Corrective action and preventive action (CAPA) effectiveness\no Quality assurance unit oversight, and written procedures\no Address how your firm will ensure all phases of investigations are appropriately conducted.\nA comprehensive review of root cause investigations for deviations related to biological particulate matter found in your products, including incoming inspection activities and subsequent CAPA activities. Provide supporting documents, including data generated and effectiveness evaluations.\nAn independent, retrospective review of all critical investigations (including each in-process, release, and stability test specification failure) for the last three years as of the date of this letter. Evaluate the adequacy of each investigation, including but not limited to, the following:\no Determine whether a thorough review of production (e.g., batch manufacturing records, adequacy of the manufacturing steps, suitability of equipment\u002Ffacilities, variability of raw materials, process capability, deviation history, complaint history, batch failure history) was conducted.\no Assess sufficiency of review of related data and investigations to identify if there are potential systemic linkages.\no Evaluate adequacy of scope, rigor, staff competencies, scientific\u002Fanalytical foundation, root cause determinations, and CAPA.\no Summary of findings of the assessment for each of the above elements.\nAn independent assessment and remediation plan for your CAPA program. Provide a report that evaluates whether the program includes effective root cause analysis, ensures CAPA effectiveness, analyzes investigations trends, improves the CAPA program whenever needed, ensures final quality assurance unit decision authority, and is fully supported by executive management.\nA comprehensive evaluation of your program to prevent endotoxin contamination risks and associated CAPA, including but not limited to:\no Containers and Closures ((b)(4) packaging components)\no Ingredients\no (b)(4) systems\no Process and procedural controls\no Design and control of your equipment, including preventive maintenance and repairs\no Manufacturing environment\nAn independent, comprehensive review of your environmental monitoring (EM) program to ensure vigilant, timely detection and response to potential product contamination hazards in your manufacturing environment. This assessment should include, but not be limited to, the following:\no Establishing appropriate limits\no Sampling methods\no Sampling locations and frequencies\no Trend analysis\no Appropriate investigation of deviations and adverse trends\no Comprehensive CAPA plan based on the findings of the assessment\nA comprehensive, independent review of your process simulation (e.g., media fill) program to ensure accurate simulations of commercial aseptic manufacturing operations, including but not limited to appropriate incorporation of worst-case conditions.\nAn independent assessment of vials rejected for hair contamination, and an update that summarizes all analyses performed on suspected foreign matter identified as part of batch production (within expiration date) or after testing retains related to complaints.\nThe most updated status on your supplier quality investigations for stoppers and any remediation efforts. Include the following:\no Incoming component inspection results\no Defect trends and Acceptable Quality Limit performance\no Whether biological particulates have been identified in any incoming (b)(4) packaging components in the last three years\n2. Your firm failed to establish and follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile, and that include validation of all aseptic and sterilization processes (21 CFR 211.113(b)).\nInadequate Aseptic Process Simulations (Media Fills)\nYour media fills failed to accurately simulate aseptic manufacturing operations.\nAt the time of the inspection, your firm used a sampling approach to determine a representative number of each intervention necessary to simulate your aseptic processes. A review showed that your media fill simulations did not adequately represent your maximum aseptic intervention counts (e.g., clearing stoppers in the (b)(4)\u002Ftrack, (b)(4) application, (b)(4) adjustment, removing vials from the (b)(4)). Additionally, inherent interventions (e.g., stopper additions, vial loading) are not documented in your batch records, which has the consequence of inadequate assessment of the risks these interventions present during actual aseptic production. Also, data indicated that the number of units in your media fills was insufficient.\nInadequate documentation of interventions was the subject of findings from FDA’s 2022 inspection.\nIn your response, you acknowledge some interventions did not simulate the maximum risk to your aseptic processes. You commit to implement an intervention docking and tracking system and enhanced oversight of related data. You state that you will ensure thorough review of batch intervention data in the future to support simulation of inherent and corrective interventions using an appropriate worst-case approach.\nYour response is inadequate. We acknowledge your commitment to conduct appropriate media fill simulations for your aseptic processing lines. However, you do not address the need for sufficient media fill batch sizes and your response lacks sufficient detail on how you will document and track interventions.\nWhen the potential for contamination is higher, as it is with your (b)(4) processing lines surrounded by barrier (b)(4), the number of units in a media fill should be the same as, or approach, the maximum production batch size. If a media fill program fails to incorporate contamination risk factors and closely simulate actual drug product exposure, the state of process control and assurance of sterility cannot be accurately assessed. Furthermore, your (b)(4) aseptic processing lines require an inordinate number of interventions and there is a need for fundamental design remediations. Notably, media fills cannot justify unsuitable manufacturing lines and processing conditions.\nAseptic Technique and Poor Cleanroom Behavior\nWe observed poor aseptic practices and inadequate oversight. These deviations included, but were not limited to, the following:\nOperators opening and closing (b)(4) doors with sharp movements while performing (b)(4) aseptic loading of (b)(4).\nOperators repeatedly contacted the (b)(4) barrier (b)(4) with their head and upper torso, including during (b)(4) installation and (b)(4) set up.\nOperators (b)(4) clamps over the (b)(4) sterile end of tubing (which conveys the sterile formulation) during setup activities.\nIn your response, you discuss your ongoing efforts to improve your aseptic operations, and you commit to engaging a third-party consultant to assess your aseptic operation oversight. Also, you commit to implementing a standardized interview template when investigations involving personnel activities or interventions relate to human error. Additionally, you commit to improving classified area material handling.\nYour response fails to sufficiently acknowledge design flaws including, but not limited to, inadequate processing line layout, ergonomic deficiencies, excessive need for (b)(4) manipulations, insufficient barrier protection to provide adequate separation from surrounding areas, and other fundamental issues.\nThe ISO 5 (Grade A) area is critical because sterile products are exposed during aseptic production and therefore vulnerable to contamination if operations are not well designed and diligently controlled. Your aseptic processes should be designed, and operations executed, to prevent contamination hazards to your sterile product. Flaws in the design of cleanrooms and aseptic processing lines, or improper execution of operations, can promote an influx of contamination into the critical processing area.\nSee FDA’s guidance document Sterile Drug Products Produced by Aseptic Processing – Current Good Manufacturing Practice to help you meet the CGMP requirements when manufacturing sterile drugs using aseptic processing at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71026\u002Fdownload.\nIn response to this letter, provide:\nA comprehensive, independent risk assessment of all contamination hazards with respect to your aseptic processes, equipment, and facilities, including but not limited to, the following:\no All human interactions within the ISO 5 area (e.g., risk reduction or elimination of (b)(4) interventions wherever possible)\no Equipment suitability (e.g., reliability, capability, ergonomics, placement) and sufficient cleanroom space\no Air quality in the ISO 5 area and surrounding room including, but not limited to, air volume and flow\no Facility layout\no Personnel flow and material flow (movement throughout all rooms used to conduct and support sterile operations and all material transfers)\no Disinfection practices and procedures\no Specific CAPA recommendations that will comprehensively address the design and control hazards identified in the risk assessment\no A detailed remediation plan with timelines to address the findings of the contamination hazards risk assessment. Describe specific tangible, comprehensive improvements to be made to aseptic processing operation design and control of your (b)(4) processing lines surrounded by barrier (b)(4) and explain how this CAPA plan will thoroughly and robustly remediate your deficient (b)(4) aseptic processing lines.\nYour systematic plan to assure adherence to appropriate aseptic practices, cleanroom behavior, and written procedures, including but not limited to, an independent assessment of the following with accompanying CAPA:\no Suitability of actual practices based on extensive retrospective review and prospective observation of aseptic processing operations\no Deficiencies in production management oversight, and identification of specific improvements to ensure effective and routine supervisory oversight for all batches\no Frequency and depth of quality unit oversight (e.g., audit, ad hoc, daily interactions) of aseptic processing and its support operations\no Adequacy of written procedures and operational ergonomics\nThe assessment should also evaluate how poor aseptic technique and cleanroom behavior may have affected the quality and sterility of your drugs.\nIn an easily searchable tabular format, your updated plan to expedite the transfer of manufacturing from your Building (b)(4) aseptic filling lines to your Building (b)(4) lines without creating drug shortages. Include a list of backup contract manufacturing organizations that would be utilized in the event you are unable to ensure supply chain continuity.\n3. Your firm failed to establish adequate control procedures to monitor the output and to validate the performance of those manufacturing processes that may be responsible for causing variability in the characteristics of in-process material and the drug. Your firm failed to perform operations within specifically defined areas of adequate size and to have separate or defined areas or such other control systems necessary to prevent contamination or mix-ups in aseptic processing areas (21 CFR 211.110(a) and 21 CFR 211.42(c)(10)).\nInadequate Visual Inspection Program\nYour visual inspection program is inadequate to ensure your sterile injectable drug products are essentially free of visible particulates and defects. For example:\nYou categorized all non-glass particulate, regardless of material type (i.e., hair) as major, which means more severe particulates of biological origin are not considered critical.\n(b)(4) visible particulate inspection systems often exhibited low detectability and high variability regardless of particle type (e.g., glass, white particulate, black particulate) and size.\nYour probability of detection (POD) of particulates using (b)(4) visual inspection was inadequate. Your methods often exhibit PODs significantly less than (b)(4)% for particulate matter defects. In addition, glass particulates in the visible range were not consistently detected.\nYou lacked defect limits for specific types of non-glass particulate matter in the visual inspection program.\nIn your response, you recognize that studies did not generate sufficient data across increasing particulate sizes to adequately qualify your visual inspection program and that comparison reports were not completed. Additionally, you indicated that all extrinsic particulates are now classified as critical defects and acknowledge the potential loss of sterility often associated with such particulates.\nYour response is inadequate. Although you commit to evaluating the visual inspection program with the assistance of an independent third-party consultant, your response lacks a sufficient assessment of products currently on the market.\nVisual detection of particulates is a probabilistic process that depends on, among other things, ensuring that visible particulates can be reproducibly detected by highly capable systems including, but not limited to, trained personnel with appropriate visual acuity. At a minimum, your visual inspection systems should reliably be capable of detecting particulates of 150 microns or greater at a 70% probability of detection. Furthermore, written procedures governing 100% inspections for visual particulates should clearly define the number of times re-inspection may be performed. You should limit and justify re-inspections. Generally, FDA does not recommend more than one re-inspection in an attempt to release a batch with atypical defect levels1.\nInadequate Design of Facility and Equipment\nWe observed your (b)(4) processing lines (b)(4) surrounded by barrier (b)(4) under ceiling-fed high efficiency particulate air (HEPA) systems. These processing lines required frequent (b)(4) activities during equipment setup and throughout routine production and did not provide appropriate separation and protection of the ISO 5 areas. For example, we observed the following regarding these aseptic processing lines:\nThe use of (b)(4) tubing, (b)(4) clamps, and hand tools when making critical aseptic connections within the ISO 5 area that risk interruption of first-pass air and introduce contamination hazards\nThe use of barrier (b)(4) of varying lengths across each line, which provided inadequate protection of the ISO 5 processing line\nFrequent high-risk corrective interventions\nIn your response, you emphasize that your firm has been focused on your plan to transition production from your current aseptic manufacturing lines (b)(4) to your (b)(4) lines rather than updating the sterility assurance controls on your original lines. You further commit to re-evaluating and improving your aseptic processing lines with the assistance of a third-party.\nYour response is inadequate. Your response lacks sufficient detail and corrective actions for sterility assurance improvements while you continue to use your (b)(4) processing lines with their inherent design flaws.\nIn response to this letter, provide:\nA comprehensive, independent assessment and remediation plan for your visual inspection program to ensure compliance with CGMP. The assessment and remediation should include, but not be limited to, the following:\no Implementing enhancements to your 100% visible inspection program, including defining critical, major, and minor defects and the individual defect limits for drug products.\no Ensuring adequate methods, equipment, and personnel qualifications to reproducibly detect visible particulates, including particulates which historically have been identified in your operation.\no Conducting rigorous qualification studies to ensure your (b)(4) visible particulate inspection systems consistently and reproducibly detects the variety of visible particulates encountered in your drug products.\no For drug products that are difficult to inspect (e.g., (b)(4) containers), implementing destructive testing or other advanced technologies (e.g., (b)(4)) as appropriate, with statistically significant sample sizes to test for defects.\no Incorporating product-specific knowledge, process experience, deviation investigation analysis, recall\u002Fcomplaint data, and quality risk management to improve the visual inspection program.\nYour associated remediations to your visual inspection program, including any newly established written procedures, equipment, and methods. Include a summary of the review and recommendations made by your independent consultant.\nVisible Particulate Contamination\nWe encourage the use of suitable (b)(4) visual inspection for particulates to augment the (b)(4) visual inspection program. (b)(4) methods should be rigorously studied, and qualified, to assess their capability and robustness under various conditions, machine settings, container-closure sizes, defect types, product characteristic, and other variables. In addition, any use of (b)(4) particulate inspection as an adjunct method does not supplant the need for (b)(4) visual inspection for various other attributes (e.g., cracks; myriad defects of container or closure; (b)(4) issues, volume, atypical, (b)(4), or other appearance defects).\nQuality Systems\nYour firm’s quality systems are inadequate. For guidance on establishing and maintaining CGMP-compliant quality systems, see FDA guidance documents: Q8(R2) Pharmaceutical Development at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71535\u002Fdownload,\nQ9(R1) Quality Risk Management at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F167721\u002Fdownload, and Q10 Pharmaceutical Quality System at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71553\u002Fdownload.\nCGMP Consultant\nBased upon the nature of the violations we identified at your firm and because you failed to correct repeat violations, you should engage a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements.\nYour use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\nRecall Discussion\nOn July 9, 2026, FDA held a teleconference with your firm to discuss voluntary recall. During this call, FDA informed you that our inspection revealed that drug products produced at Fresenius Kabi USA LLC contain particulate of biological origin, do not meet CGMP requirements, and are considered adulterated. Your firm initially released these adulterated batches for distribution based on your assertion that product testing results were adequate. Following the recall discussion with FDA, your firm committed to recalling six batches of drug products. As a result, on July 16, 2026, recalls were initiated for:\nGlycopyrrolate Injection, USP\nLidocaine HCl Injection, USP\nRopivacaine Hydrocholoride Injection, USP\nLidocaine HCl Injection, USP\nRequest for a Meeting with FDA\nAfter you submit your response to this warning letter, we recommend you reach out to this office to arrange for a teleconference to discuss your corrective and preventive actions in detail. Please direct your request to Christina Reyes at christina.reyes@fda.hhs.gov and cc: CDER-OC-OMQ-Communications@fda.hhs.gov.\nConclusion\nYou are responsible for investigating and determining the root causes of any violations and implementing corrective and preventative measures to ensure future and sustained compliance so that these violations and any others do not occur.\nUnresolved violations may prevent other Federal agencies from awarding contracts. Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\nIf you are considering an action that is likely to lead to a disruption in the supply of drugs produced at your facility, FDA requests that you contact CDER’s Drug Shortages Staff immediately, at drugshortages@fda.hhs.gov, so that FDA can work with you on the most effective way to bring your operations into compliance with the law. Contacting the Drug Shortages Staff also allows you to meet any obligations you may have to report discontinuances or interruptions in your drug manufacture under 21 U.S.C. 356c(b). This also allows FDA to consider, as soon as possible, what actions, if any, may be needed to avoid shortages and protect the health of patients who depend on your products.\nSend your written response to CDER-OC-OMQ-Communications@fda.hhs.gov within fifteen (15) business days of receipt of this letter2. Identify your written response with FEI 1450022 and ATTN: Carrie A. Hughes in the subject line of the email.\nIf you have information that you believe demonstrates that your products are not in violation of the FD&C Act and FDA regulations, include that information for our consideration.\nPlease note FDA posts warning letters on www.FDA.gov.\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research\nU.S. Food and Drug Administration\ncc: Mr. Steven R. Nowicki\nPlant Manager, Fresenius Kabi USA LLC\nMelrose Park, IL\n(b)(4)\n_________________\n1 See FDA’s draft guidance document Inspection of Injectable Products for Visible Particulates to help you meet the CGMP requirements pertaining to visible particulate inspections of sterile injectable drug products at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F154868\u002Fdownload.\n2 Under program enhancements for the Generic Drug User Fee Amendments (GDUFA) reauthorization for fiscal years (FYs) 2023-2027, also known as the GDUFA III Commitment Letter, your facility may be eligible for a Post-Warning Letter Meeting to obtain preliminary feedback from FDA on the adequacy and completeness of your corrective action plans.","Fresenius Kabi USA LLC","fresenius-kabi-usa-llc-733107-09222026","2026-10-14T12:31:16.41489+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ffresenius-kabi-usa-llc-733107-09222026","2026-11-10T01:02:16.121874+00:00","Warning Letter","Issued","2026-09-29","733107","Drugs","Mr. Pierluigi Antonelli","2026-10-14T12:34:55.56+00:00","VIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED","320-26-129","2026-09-22",{"id":33,"raw":34,"subject":40,"body_html":41,"body_text":42,"firm_name":43,"letter_id":44,"created_at":45,"fei_number":19,"letter_url":46,"updated_at":47,"action_type":22,"case_status":23,"posted_date":48,"marcs_cms_no":49,"product_type":50,"closeout_date":19,"issuing_office":38,"recipient_name":51,"body_fetched_at":52,"delivery_method":53,"recipient_title":19,"reference_number":19,"action_taken_date":54,"medical_device_id":19,"response_letter_date":19},1585,[35,36,37,38,39,13,13,13],"\u003Ctime datetime=\"2024-03-05T14:20:00Z\">03\u002F05\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-01-04T05:00:00Z\">01\u002F04\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ffresenius-kabi-ag-671249-01042024\">Fresenius Kabi AG\u003C\u002Fa>","Center for Devices and Radiological Health","CGMP\u002FQSR\u002FMedical Devices\u002FAdulterated\u003Cbr \u002F>\r\n","CGMP\u002FQSR\u002FMedical Devices\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Pierluigi Antonelli\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Fresenius Kabi AG\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>Else-Kroner-Str. 1\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>61352\u003C\u002Fspan> \u003Cspan>Bad Homburg\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Germany\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n  \u003Cdiv>\n    \u003Cdiv>Secondary Issuing Offices\u003C\u002Fdiv>\n          \u003Cdiv>\n              \u003Cdiv>    \u003Cbr>\n    \n     \n        \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n    \n    \n    \n    \n\u003C\u002Fdiv>\n              \u003C\u002Fdiv>\n      \u003C\u002Fdiv>\n\n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003Cbr>\nCMS# 671249\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>January 4, 2024\u003Cbr>\n\u003Cbr>\nDear Mr. Antonelli:\u003C\u002Fp>\n\n\u003Cp>During an inspection of your firm, Fresenius Kabi USA, LLC, located at 50 High Street, Suite 50, North Andover, MA 01845-2620 on August 15, 2023, through September 7, 2023, an investigator from the United States Food and Drug Administration (FDA) determined that your firm is a specification developer and manufacturer of the Ivenix Infusion System which includes the Ivenix Infusion Pump, Infusion Safety Management Software, and Intravascular Administration Set. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003C\u002Fp>\n\n\u003Cp>This inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, \u003Cu>Code of Federal Regulations\u003C\u002Fu> (CFR), Part 820.\u003C\u002Fp>\n\n\u003Cp>We received responses from Benjamin Powers, Vice President, Research and Development, and Rebecca McCandless, Senior Director, Quality, dated September 28, 2023, October 27, 2023, November 28, 2023, and December 28, 2023, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>1. Failure to establish procedures for implementing corrective and preventive action, as required by 21 CFR § 820.100(a). Specifically, your CORRECTIVE AND PREVENTIVE PROCEDURE, Doc.ID: 410-0013-01, Revisions 12, 13, and 14, are inadequate in that:\u003C\u002Fp>\n\n\u003Cp>a. Health risk assessments, health hazard evaluations, and root cause analyses investigations are routinely not completed within the required ten-day timeframe, per your CORRECTIVE AND PREVENTIVE PROCEDURE, Doc.ID: 410-0013-01. Specifically,\u003C\u002Fp>\n\n\u003Cp>i. CAPA-00041 was initiated on July 20, 2022, to address \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> on the Ivenix Large Volume Infusion Pump, and the Health Risk Assessment\u002FHealth Hazard Evaluation has been in draft form since January 3, 2023, and was still open during the current FDA inspection.\u003C\u002Fp>\n\n\u003Cp>ii. CAPA-00047 was initiated on March 22, 2023, after becoming aware that your contract manufacturer continued to use the previous revision of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> component, and the Health Risk Assessment\u002FHealth Hazard Evaluation has been in draft form since July 10, 2023, and was still open during the current FDA inspection.\u003C\u002Fp>\n\n\u003Cp>b. Your ROOT CAUSE ANALYSIS, 420-0001-01, Revision 2.0 Work Instruction has not been adequately implemented, and the root cause analysis investigation conducted as part of CAPA-00040 is inadequate. CAPA-00040 was initiated on May 13, 2022, after becoming aware of a software bug, indicates that your out-of-business firmware vendor had previously conducted a software code review, but no further documentation of such review is available, and no further root cause investigation is documented. Additionally, the quality issue related to CAPA-00040, resulted in the Class I recall RES 90845, initiated on September 8, 2022.\u003C\u002Fp>\n\n\u003Cp>c. The verification of effectiveness of CAPA-00044, which was initiated on January 13, 2023 to address fluid ingress into the Ivenix Large Volume Infusion Pump, is inadequate in that the required validation was not conducted. Specifically, a leak test, as required by the verification and effectiveness plan and the verification protocol was not followed as both the assembler and inspector did not use magnification to conduct the visual inspection. Finally, CAPA-00044 resulted in the Class I recall RES 91783, initiated on March 10, 2023, and is still on-going.\u003C\u002Fp>\n\n\u003Cp>The adequacy of your firm’s responses cannot be determined at this time. Your responses document that you have implemented corrections to the specific instances detailed above. Your responses also indicate that you plan to implement additional corrective actions by updating related written procedures and work instructions, as well as implementing training. Alternatively, the adequacy of your responses cannot be determined at this time, as there is no available evidence to document that your planned corrective actions will prevent recurrence of these violations.\u003C\u002Fp>\n\n\u003Cp>2. Failure to establish and maintain procedures to control the design of the device in order to ensure that specified design requirements are met, as required by 21 CFR § 820.30(a). Specifically, the ECO-00089 Impact Assessment and FAI-3552, do not document that your firm evaluated the apparent risk of the continued use of the Rev B \u003Cstrong>(b)(4) \u003C\u002Fstrong>or evaluated to ensure that specified design requirements could continue to be met, as required per the CHANGE ORDER PROCESSING, Doc.ID: 410-0011-01, Rev: 17 and CHANGE CONTROL, Doc.ID: 410-0011-01, Rev: 13 procedures. Additionally, your firm has no supporting evidence to demonstrate verification of the remaining inventory quantities of the Rev B \u003Cstrong>(b)(4)\u003C\u002Fstrong>, nor does your firm have documentation to demonstrate how long the Rev B component continued to be used by your supplier\u002Fvendor after the implementation of ECO-00089.\u003C\u002Fp>\n\n\u003Cp>We have reviewed your responses and determined they are inadequate. Your responses document that FAI-3552 has been updated to include a justification for the continued use of the Rev B \u003Cstrong>(b)(4)\u003C\u002Fstrong> component and that your firm planned to update the CHANGE ORDER PROCESSING, Doc.ID: 410-0011-01 on\u002Faround November 15, 2023. Additionally, your responses do not indicate that you performed a retrospective review of design changes to determine if you adequately documented the \u003Cstrong>(b)(4)\u003C\u002Fstrong> justification for other changes that have been made. Therefore, your responses are inadequate, as there is no available evidence to document that your planned corrective actions will prevent recurrence of these violations.\u003C\u002Fp>\n\n\u003Cp>3. Failure to establish procedures for validating the device design and failure to include software validation and risk analysis, where appropriate, as required by 21 CFR § 820.30(g). Specifically, your risk analysis is inadequate in that it was not updated as required per Risk Management Procedure, 410-0009-01, Revision: 17.\u003C\u002Fp>\n\n\u003Cp>The Ivenix Large Volume Pump’s Software Failure Analysis, 550-0015-04, Rev 2.0, did not include the hazard of extended start-up time to achieve the stated flow rate accuracy of +\u002F-5%, nor was it revised to include this hazard after becoming aware of a product defect that allowed the device to exhibit this issue when infusing fluids at a rate of &gt;50 ml\u002Fhr. and &lt;200 ml\u002Fhr., as documented and identified in CAPA-00038 and FAI-4446. CAPA-00038 was initiated on April 1, 2022, due to startup time failures in high flow of the Ivenix Large Volume Infusion Pumps. Furthermore, this quality issue resulted in the issuance of a customer notification on April 22, 2022, and ultimately the Class II recall RES 92973.\u003C\u002Fp>\n\n\u003Cp>We have reviewed your responses and determined they are inadequate. Your responses document that your risk analysis has been updated and that your firm planned to update the related risk analysis procedures and provide training to affected personnel on\u002Faround \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Your responses are inadequate because they do not indicate that you plan to perform a retrospective review of CAPAs to ensure your risk analysis has been adequately updated, and there is no available evidence to document that your planned corrective actions will prevent recurrence of these violations.\u003C\u002Fp>\n\n\u003Cp>4. Failure to establish procedures for the identification, documentation, validation, or where appropriate verification, review, and approval of design changes before their implementation, as required by 21 CFR § 820.30(i). Specifically, the design change documented in FAI-3552, which was meant to address an issue found in reliability testing of the Ivenix Large Volume Infusion Pumps, was not verified or validated as required by the verification requirements outlined in FAI-3552, or as required by your PROBLEM RESOLUTION PROCESS, 410-0053-01, Rev: 02 procedure.\u003C\u002Fp>\n\n\u003Cp>The adequacy of your firm’s responses cannot be determined at this time. Your responses indicate that you planned to update your Change Order Processing and Defect Resolution procedures, on\u002Faround \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and \u003Cstrong>(b)(4)\u003C\u002Fstrong>, respectively. Alternatively, the adequacy of your responses cannot be determined at this time, as there is no available evidence to document that your planned corrective actions will prevent recurrence of these violations.\u003C\u002Fp>\n\n\u003Cp>Our inspection also revealed that your firm’s Ivenix Infusion System is misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under Section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 - Medical Device Reporting. Significant violations include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>1. Failure to report to us the information required by § 803.52 in accordance with the requirements of § 803.12(a), no later than 30 calendar days after the day that you receive or otherwise become aware of information, from any source, that reasonably suggests that a device that you market has malfunctioned and this device or a similar device that you market would be likely to cause or contribute to a death or serious injury, if the malfunction were to recur, as required by 21 CFR § 803.50(a)(2).\u003C\u002Fp>\n\n\u003Cp>For example, the information included for Complaints CMT-00401, CMT-00429, CMT-00460, CMT-00477, CMT-00487, CMT-00493, CMT-00494, CMT-00511, CMT-00512, CMT-00519, and CMT-00535 reasonably suggests that your firm’s Ivenix Infusion System malfunctioned (i.e. loss of electrical function) while in use. Although your firm submitted the corresponding MDRs (MDR# 3014732157-2023-00107, 3014732157-2023-001078, 3014732157-2023-001079, 3014732157-2023-00110, 3014732157-2023-00111, 3014732157-2023-00112, 3014732157-2023-00113, 3014732157-2023-00114, 3014732157-2023-00115, 3014732157-2023-00116, 3014732157-2023-00080) for each of these reportable events, the MDRs were not received by FDA within the required 30 calendar day timeframe.\u003C\u002Fp>\n\n\u003Cp>The adequacy of your firm’s responses cannot be determined at this time. Your responses indicate that your firm conducted a retrospective review of complaints associated with all the malfunctions identified during the inspection and has submitted the newly identified MDRs. Furthermore, your firm committed to rectifying regulatory gaps in your complaint investigation process and are in the process of conducting a retrospective review of all complaints received since March 1, 2022, in alignment with the revised process. However, your responses do not include documentation of the completion of these corrective actions as they are currently ongoing.\u003C\u002Fp>\n\n\u003Cp>2. Failure to adequately develop, maintain, and implement written MDR procedures as required by 21 CFR § 803.17. For example, during the inspection, your firm presented the following documents:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“Reporting of Medical Device Events”, Global-SOP-VI-000003141, Version 4.0, dated 31-Oct-2022\u003C\u002Fli>\n\t\u003Cli>“Product Complaint Management”, Doc. ID: 410-0022-01, Rev. 11, undated\u003C\u002Fli>\n\t\u003Cli>“Complaint management – Propel DB Work Instruction”, Doc. ID: 420-0023-01, Rev. 08, undated\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Upon a collective review of these documents as your firm’s MDR procedure, the following deficiencies were noted:\u003C\u002Fp>\n\n\u003Cp>a. The procedure does not establish internal systems that provide for timely and effective identification, communication, and evaluation of events that may be subject to MDR requirements, as required by 21 CFR § 803.17(a)(1). For example:\u003Cbr>\n&nbsp; &nbsp; i. There are no definitions of what your firm will consider to be a reportable event under 21 CFR § Part 803. The exclusion of definitions from 21 CFR § 803.3 for the terms “become aware”, “caused or contributed”, “malfunction”, “MDR reportable event”, and “serious injury”, and the definition for the term “reasonably suggests”, found in 21 CFR § 803.20(c)(1) may lead your firm to make an incorrect reportability decision when evaluating a complaint that may meet the criteria for reporting under 21 CFR § 803.50(a).\u003Cbr>\n&nbsp; &nbsp; ii. The procedure, as written, combines language from the requirements of other regulatory or competent authorities with the requirements in 21 CFR § 803 in a manner that will result in incomplete, inadequate, or even non-reporting of adverse events that meet the reportability requirements under 21 CFR § 803.\u003C\u002Fp>\n\n\u003Cp>b. The procedure does not establish internal systems that provide for a standardized\u003Cbr>\nreview process to determine when an event meets the criteria for reporting under this part, as required by 21 CFR § 803.17(a)(2). For example, although the procedure includes instructions for how your firm will evaluate information about an event to make a reportability decision, it fails to include instructions for\u003C\u002Fp>\n\n\u003Cp>c. The procedure does not establish internal systems that provide for timely transmission of complete medical device reports, as required by 21 CFR § 803.17(a)(3). Specifically, the procedure does not include:\u003Cbr>\n&nbsp; &nbsp; i. Instructions for how to obtain and complete the FDA 3500A form.\u003Cbr>\n&nbsp; &nbsp; ii. The circumstance under which your firm must submit initial 30 days, supplement, or follow-up, 5-day reports and the requirements for such reports.\u003Cbr>\n&nbsp; &nbsp; iii. A process for submitting initial and supplement or follow-up reports to FDA in an electronic format that FDA can process, review and archive in accordance with 21CFR 803.12(a).\u003Cbr>\n&nbsp; &nbsp; iv. How your firm will ensure that all information reasonably known to you is submitted for each event. Specifically, which sections of the Form 3500A will need to be completed to include all information found in your firm’s possession and any information that becomes available as a result of a reasonable follow-up within your firm.\u003C\u002Fp>\n\n\u003Cp>d. The procedure does not describe how your firm will address documentation and recordkeeping requirements, as required by 21 CFR § 803.17(b), including:\u003Cbr>\n&nbsp; &nbsp; i. Information that was evaluated to determine if an event was reportable.\u003Cbr>\n&nbsp; &nbsp; ii. Documentation of the deliberations and decision-making processes used to determine if a device-related death, serious injury, or malfunction was or was not reportable, as required under 21 CFR § 803.18(b)(1)(i).\u003C\u002Fp>\n\n\u003Cp>Additionally, it is important to note that your procedure acknowledged that your firm's Quality Assurance operations, situated at your sister facility in Lake Zurich, Illinois, was designated to make the reportability determination and submit the MDRs. However, your firm has ultimate responsibility for ensuring that MDR reportable events for devices it markets are submitted within the required regulatory timeframe.\u003C\u002Fp>\n\n\u003Cp>Your firm’s responses do not adequately address the procedural deficiencies as they were not included in the FDA Form 483.\u003C\u002Fp>\n\n\u003Cp>Our inspection also revealed that your firm’s Ivenix Infusion System which includes the Ivenix Infusion Pump, Infusion Safety Management Software, and Intravascular Administration Set devices, are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 806 – Medical Devices; Reports of Corrections and Removals. Significant violations include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>Failure to submit a correction or removal initiated to reduce a risk to health posed by the device and required to be reported to the FDA by 21 CFR § 806.10(a), was not reported in writing within 10-working days of initiating such correction or removal, as required by 21 CFR § 806.10(b).\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm issued a customer notification letter on April 22, 2022, and implemented a related field correction and software update by July 26, 2022, as documented by FAI-4446, FAI-4237, and CAPA-00038. Alternatively, your firm did not submit the required written report of this correction and removal to the FDA until August 23, 2023, approximately sixteen months after the customer notification letter was issued and approximately thirteen months after implementing the field correction and software update. FDA classified this correction and removal, RES 92973, as a Class II recall on September 25, 2023.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s responses and concluded that they are not adequate. Your responses confirm that your firm submitted a written report documenting RES 92973 on August 23, 2023, and a termination request on October 25, 2023. Although, your responses do not address the correction and removal reporting well beyond the required ten-day timeframe, per 21 CFR § 806.10(b).\u003C\u002Fp>\n\n\u003Cp>Your firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\n\n\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\u003C\u002Fp>\n\n\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\n\n\u003Cp>Your firm’s response should be sent to: Gina Brackett, Director of Compliance Branch, at oradevices1firmresponse@fda.hhs.gov. Refer to CMS # 671249 when replying. If you have any questions about the contents of this letter, please contact Katelyn Staub-Zamperini, Compliance Officer, at 412-644-3394 ext. 20 or katelyn.staub-zamperini@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>We are also proposing a virtual Regulatory Meeting on Friday, January 19, 2024, at 2:00 PM EST to discuss our concerns. At this meeting, you should be prepared to discuss the status of your proposed corrections. Please confirm this scheduled meeting with Ms. Staub-Zamperini at the above contact information.\u003C\u002Fp>\n\n\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\n\n\u003Cp>Sincerely yours,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Joseph Matrisciano, Jr.\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Medical Device and Radiological Health\u003Cbr>\nDivision 1\u002FEast\u003C\u002Fp>\n\n\u003Cp>\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Kellie B. Kelm, Ph.D.\u003Cbr>\nActing Director\u003Cbr>\nOHT3: Office of GastroRenal, ObGyn, General\u003Cbr>\nHospital and Urology Devices\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nCenter for Devices and Radiological Health\u003C\u002Fp>\n\n\u003Cp>cc:\u003C\u002Fp>\n\n\u003Cp>Benjamin Powers, Vice President,\u003Cbr>\nResearch and Development,\u003Cbr>\nFresenius Kabi USA, LLC,\u003Cbr>\n50 High Street, Suite 50,\u003Cbr>\nNorth Andover, MA 01845\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nPierluigi Antonelli\n\nRecipient Title\n\nCEO\n\nFresenius Kabi AG\n\nElse-Kroner-Str. 1\n\n61352 Bad Homburg\n\nGermany\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nSecondary Issuing Offices\n\nUnited States\n\nWARNING LETTER\n\nCMS# 671249\n\nJanuary 4, 2024\n\nDear Mr. Antonelli:\n\nDuring an inspection of your firm, Fresenius Kabi USA, LLC, located at 50 High Street, Suite 50, North Andover, MA 01845-2620 on August 15, 2023, through September 7, 2023, an investigator from the United States Food and Drug Administration (FDA) determined that your firm is a specification developer and manufacturer of the Ivenix Infusion System which includes the Ivenix Infusion Pump, Infusion Safety Management Software, and Intravascular Administration Set. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\n\nThis inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820.\n\nWe received responses from Benjamin Powers, Vice President, Research and Development, and Rebecca McCandless, Senior Director, Quality, dated September 28, 2023, October 27, 2023, November 28, 2023, and December 28, 2023, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\n\n1. Failure to establish procedures for implementing corrective and preventive action, as required by 21 CFR § 820.100(a). Specifically, your CORRECTIVE AND PREVENTIVE PROCEDURE, Doc.ID: 410-0013-01, Revisions 12, 13, and 14, are inadequate in that:\n\na. Health risk assessments, health hazard evaluations, and root cause analyses investigations are routinely not completed within the required ten-day timeframe, per your CORRECTIVE AND PREVENTIVE PROCEDURE, Doc.ID: 410-0013-01. Specifically,\n\ni. CAPA-00041 was initiated on July 20, 2022, to address (b)(4) and (b)(4) on the Ivenix Large Volume Infusion Pump, and the Health Risk Assessment\u002FHealth Hazard Evaluation has been in draft form since January 3, 2023, and was still open during the current FDA inspection.\n\nii. CAPA-00047 was initiated on March 22, 2023, after becoming aware that your contract manufacturer continued to use the previous revision of the (b)(4) component, and the Health Risk Assessment\u002FHealth Hazard Evaluation has been in draft form since July 10, 2023, and was still open during the current FDA inspection.\n\nb. Your ROOT CAUSE ANALYSIS, 420-0001-01, Revision 2.0 Work Instruction has not been adequately implemented, and the root cause analysis investigation conducted as part of CAPA-00040 is inadequate. CAPA-00040 was initiated on May 13, 2022, after becoming aware of a software bug, indicates that your out-of-business firmware vendor had previously conducted a software code review, but no further documentation of such review is available, and no further root cause investigation is documented. Additionally, the quality issue related to CAPA-00040, resulted in the Class I recall RES 90845, initiated on September 8, 2022.\n\nc. The verification of effectiveness of CAPA-00044, which was initiated on January 13, 2023 to address fluid ingress into the Ivenix Large Volume Infusion Pump, is inadequate in that the required validation was not conducted. Specifically, a leak test, as required by the verification and effectiveness plan and the verification protocol was not followed as both the assembler and inspector did not use magnification to conduct the visual inspection. Finally, CAPA-00044 resulted in the Class I recall RES 91783, initiated on March 10, 2023, and is still on-going.\n\nThe adequacy of your firm’s responses cannot be determined at this time. Your responses document that you have implemented corrections to the specific instances detailed above. Your responses also indicate that you plan to implement additional corrective actions by updating related written procedures and work instructions, as well as implementing training. Alternatively, the adequacy of your responses cannot be determined at this time, as there is no available evidence to document that your planned corrective actions will prevent recurrence of these violations.\n\n2. Failure to establish and maintain procedures to control the design of the device in order to ensure that specified design requirements are met, as required by 21 CFR § 820.30(a). Specifically, the ECO-00089 Impact Assessment and FAI-3552, do not document that your firm evaluated the apparent risk of the continued use of the Rev B (b)(4) or evaluated to ensure that specified design requirements could continue to be met, as required per the CHANGE ORDER PROCESSING, Doc.ID: 410-0011-01, Rev: 17 and CHANGE CONTROL, Doc.ID: 410-0011-01, Rev: 13 procedures. Additionally, your firm has no supporting evidence to demonstrate verification of the remaining inventory quantities of the Rev B (b)(4), nor does your firm have documentation to demonstrate how long the Rev B component continued to be used by your supplier\u002Fvendor after the implementation of ECO-00089.\n\nWe have reviewed your responses and determined they are inadequate. Your responses document that FAI-3552 has been updated to include a justification for the continued use of the Rev B (b)(4) component and that your firm planned to update the CHANGE ORDER PROCESSING, Doc.ID: 410-0011-01 on\u002Faround November 15, 2023. Additionally, your responses do not indicate that you performed a retrospective review of design changes to determine if you adequately documented the (b)(4) justification for other changes that have been made. Therefore, your responses are inadequate, as there is no available evidence to document that your planned corrective actions will prevent recurrence of these violations.\n\n3. Failure to establish procedures for validating the device design and failure to include software validation and risk analysis, where appropriate, as required by 21 CFR § 820.30(g). Specifically, your risk analysis is inadequate in that it was not updated as required per Risk Management Procedure, 410-0009-01, Revision: 17.\n\nThe Ivenix Large Volume Pump’s Software Failure Analysis, 550-0015-04, Rev 2.0, did not include the hazard of extended start-up time to achieve the stated flow rate accuracy of +\u002F-5%, nor was it revised to include this hazard after becoming aware of a product defect that allowed the device to exhibit this issue when infusing fluids at a rate of >50 ml\u002Fhr. and \u003C200 ml\u002Fhr., as documented and identified in CAPA-00038 and FAI-4446. CAPA-00038 was initiated on April 1, 2022, due to startup time failures in high flow of the Ivenix Large Volume Infusion Pumps. Furthermore, this quality issue resulted in the issuance of a customer notification on April 22, 2022, and ultimately the Class II recall RES 92973.\n\nWe have reviewed your responses and determined they are inadequate. Your responses document that your risk analysis has been updated and that your firm planned to update the related risk analysis procedures and provide training to affected personnel on\u002Faround (b)(4). Your responses are inadequate because they do not indicate that you plan to perform a retrospective review of CAPAs to ensure your risk analysis has been adequately updated, and there is no available evidence to document that your planned corrective actions will prevent recurrence of these violations.\n\n4. Failure to establish procedures for the identification, documentation, validation, or where appropriate verification, review, and approval of design changes before their implementation, as required by 21 CFR § 820.30(i). Specifically, the design change documented in FAI-3552, which was meant to address an issue found in reliability testing of the Ivenix Large Volume Infusion Pumps, was not verified or validated as required by the verification requirements outlined in FAI-3552, or as required by your PROBLEM RESOLUTION PROCESS, 410-0053-01, Rev: 02 procedure.\n\nThe adequacy of your firm’s responses cannot be determined at this time. Your responses indicate that you planned to update your Change Order Processing and Defect Resolution procedures, on\u002Faround (b)(4), and (b)(4), respectively. Alternatively, the adequacy of your responses cannot be determined at this time, as there is no available evidence to document that your planned corrective actions will prevent recurrence of these violations.\n\nOur inspection also revealed that your firm’s Ivenix Infusion System is misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under Section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 - Medical Device Reporting. Significant violations include, but are not limited to, the following:\n\n1. Failure to report to us the information required by § 803.52 in accordance with the requirements of § 803.12(a), no later than 30 calendar days after the day that you receive or otherwise become aware of information, from any source, that reasonably suggests that a device that you market has malfunctioned and this device or a similar device that you market would be likely to cause or contribute to a death or serious injury, if the malfunction were to recur, as required by 21 CFR § 803.50(a)(2).\n\nFor example, the information included for Complaints CMT-00401, CMT-00429, CMT-00460, CMT-00477, CMT-00487, CMT-00493, CMT-00494, CMT-00511, CMT-00512, CMT-00519, and CMT-00535 reasonably suggests that your firm’s Ivenix Infusion System malfunctioned (i.e. loss of electrical function) while in use. Although your firm submitted the corresponding MDRs (MDR# 3014732157-2023-00107, 3014732157-2023-001078, 3014732157-2023-001079, 3014732157-2023-00110, 3014732157-2023-00111, 3014732157-2023-00112, 3014732157-2023-00113, 3014732157-2023-00114, 3014732157-2023-00115, 3014732157-2023-00116, 3014732157-2023-00080) for each of these reportable events, the MDRs were not received by FDA within the required 30 calendar day timeframe.\n\nThe adequacy of your firm’s responses cannot be determined at this time. Your responses indicate that your firm conducted a retrospective review of complaints associated with all the malfunctions identified during the inspection and has submitted the newly identified MDRs. Furthermore, your firm committed to rectifying regulatory gaps in your complaint investigation process and are in the process of conducting a retrospective review of all complaints received since March 1, 2022, in alignment with the revised process. However, your responses do not include documentation of the completion of these corrective actions as they are currently ongoing.\n\n2. Failure to adequately develop, maintain, and implement written MDR procedures as required by 21 CFR § 803.17. For example, during the inspection, your firm presented the following documents:\n\n“Reporting of Medical Device Events”, Global-SOP-VI-000003141, Version 4.0, dated 31-Oct-2022\n\n“Product Complaint Management”, Doc. ID: 410-0022-01, Rev. 11, undated\n\n“Complaint management – Propel DB Work Instruction”, Doc. ID: 420-0023-01, Rev. 08, undated\n\nUpon a collective review of these documents as your firm’s MDR procedure, the following deficiencies were noted:\n\na. The procedure does not establish internal systems that provide for timely and effective identification, communication, and evaluation of events that may be subject to MDR requirements, as required by 21 CFR § 803.17(a)(1). For example:\n\ni. There are no definitions of what your firm will consider to be a reportable event under 21 CFR § Part 803. The exclusion of definitions from 21 CFR § 803.3 for the terms “become aware”, “caused or contributed”, “malfunction”, “MDR reportable event”, and “serious injury”, and the definition for the term “reasonably suggests”, found in 21 CFR § 803.20(c)(1) may lead your firm to make an incorrect reportability decision when evaluating a complaint that may meet the criteria for reporting under 21 CFR § 803.50(a).\n\nii. The procedure, as written, combines language from the requirements of other regulatory or competent authorities with the requirements in 21 CFR § 803 in a manner that will result in incomplete, inadequate, or even non-reporting of adverse events that meet the reportability requirements under 21 CFR § 803.\n\nb. The procedure does not establish internal systems that provide for a standardized\n\nreview process to determine when an event meets the criteria for reporting under this part, as required by 21 CFR § 803.17(a)(2). For example, although the procedure includes instructions for how your firm will evaluate information about an event to make a reportability decision, it fails to include instructions for\n\nc. The procedure does not establish internal systems that provide for timely transmission of complete medical device reports, as required by 21 CFR § 803.17(a)(3). Specifically, the procedure does not include:\n\ni. Instructions for how to obtain and complete the FDA 3500A form.\n\nii. The circumstance under which your firm must submit initial 30 days, supplement, or follow-up, 5-day reports and the requirements for such reports.\n\niii. A process for submitting initial and supplement or follow-up reports to FDA in an electronic format that FDA can process, review and archive in accordance with 21CFR 803.12(a).\n\niv. How your firm will ensure that all information reasonably known to you is submitted for each event. Specifically, which sections of the Form 3500A will need to be completed to include all information found in your firm’s possession and any information that becomes available as a result of a reasonable follow-up within your firm.\n\nd. The procedure does not describe how your firm will address documentation and recordkeeping requirements, as required by 21 CFR § 803.17(b), including:\n\ni. Information that was evaluated to determine if an event was reportable.\n\nii. Documentation of the deliberations and decision-making processes used to determine if a device-related death, serious injury, or malfunction was or was not reportable, as required under 21 CFR § 803.18(b)(1)(i).\n\nAdditionally, it is important to note that your procedure acknowledged that your firm's Quality Assurance operations, situated at your sister facility in Lake Zurich, Illinois, was designated to make the reportability determination and submit the MDRs. However, your firm has ultimate responsibility for ensuring that MDR reportable events for devices it markets are submitted within the required regulatory timeframe.\n\nYour firm’s responses do not adequately address the procedural deficiencies as they were not included in the FDA Form 483.\n\nOur inspection also revealed that your firm’s Ivenix Infusion System which includes the Ivenix Infusion Pump, Infusion Safety Management Software, and Intravascular Administration Set devices, are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 806 – Medical Devices; Reports of Corrections and Removals. Significant violations include, but are not limited to, the following:\n\nFailure to submit a correction or removal initiated to reduce a risk to health posed by the device and required to be reported to the FDA by 21 CFR § 806.10(a), was not reported in writing within 10-working days of initiating such correction or removal, as required by 21 CFR § 806.10(b).\n\nSpecifically, your firm issued a customer notification letter on April 22, 2022, and implemented a related field correction and software update by July 26, 2022, as documented by FAI-4446, FAI-4237, and CAPA-00038. Alternatively, your firm did not submit the required written report of this correction and removal to the FDA until August 23, 2023, approximately sixteen months after the customer notification letter was issued and approximately thirteen months after implementing the field correction and software update. FDA classified this correction and removal, RES 92973, as a Class II recall on September 25, 2023.\n\nWe reviewed your firm’s responses and concluded that they are not adequate. Your responses confirm that your firm submitted a written report documenting RES 92973 on August 23, 2023, and a termination request on October 25, 2023. Although, your responses do not address the correction and removal reporting well beyond the required ten-day timeframe, per 21 CFR § 806.10(b).\n\nYour firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\n\nOther federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\n\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\n\nYour firm’s response should be sent to: Gina Brackett, Director of Compliance Branch, at oradevices1firmresponse@fda.hhs.gov. Refer to CMS # 671249 when replying. If you have any questions about the contents of this letter, please contact Katelyn Staub-Zamperini, Compliance Officer, at 412-644-3394 ext. 20 or katelyn.staub-zamperini@fda.hhs.gov.\n\nWe are also proposing a virtual Regulatory Meeting on Friday, January 19, 2024, at 2:00 PM EST to discuss our concerns. At this meeting, you should be prepared to discuss the status of your proposed corrections. Please confirm this scheduled meeting with Ms. Staub-Zamperini at the above contact information.\n\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\n\nSincerely yours,\n\n\u002FS\u002F\n\nJoseph Matrisciano, Jr.\n\nProgram Division Director\n\nOffice of Medical Device and Radiological Health\n\nDivision 1\u002FEast\n\n\u002FS\u002F\n\nKellie B. Kelm, Ph.D.\n\nActing Director\n\nOHT3: Office of GastroRenal, ObGyn, General\n\nHospital and Urology Devices\n\nOffice of Product Evaluation and Quality\n\nCenter for Devices and Radiological Health\n\ncc:\n\nBenjamin Powers, Vice President,\n\nResearch and Development,\n\nFresenius Kabi USA, LLC,\n\n50 High Street, Suite 50,\n\nNorth Andover, MA 01845","Fresenius Kabi AG","fresenius-kabi-ag-671249-01042024","2026-08-18T06:42:28.994808+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ffresenius-kabi-ag-671249-01042024","2026-10-26T08:08:43.369192+00:00","2024-03-05","671249","Medical Devices","Pierluigi Antonelli","2026-08-20T00:15:38.681+00:00","VIA UNITED PARCEL SERVICE","2024-01-04",{"id":56,"raw":57,"subject":63,"body_html":64,"body_text":65,"firm_name":43,"letter_id":66,"created_at":45,"fei_number":19,"letter_url":67,"updated_at":68,"action_type":22,"case_status":23,"posted_date":69,"marcs_cms_no":70,"product_type":71,"closeout_date":19,"issuing_office":72,"recipient_name":73,"body_fetched_at":74,"delivery_method":75,"recipient_title":19,"reference_number":76,"action_taken_date":77,"medical_device_id":19,"response_letter_date":19},1819,[58,59,60,61,62,13,13,13],"\u003Ctime datetime=\"2023-09-29T21:00:00Z\">09\u002F29\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-09-14T04:00:00Z\">09\u002F14\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ffresenius-kabi-ag-657085-09142023\">Fresenius Kabi AG\u003C\u002Fa>"," Division of Biological Products Operations I ","CGMP Deviations ","CGMP Deviations","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE SIGNATURE REQUIRED\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>23-657085\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Biologics                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Dr. Christian Hauer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President of Transfusion Medicine and Cell Therapies, MedTech Division\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Fresenius Kabi AG\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>Else-Kröner-Straße 1\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>61352\u003C\u002Fspan> \u003Cspan>Bad Homburg\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Germany\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd> Division of Biological Products Operations I \u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cbr>\nSeptember 14, 2023\u003C\u002Fp>\n\n\u003Cp>23-657085\u003C\u002Fp>\n\n\u003Cp>Dear Dr. Hauer:\u003C\u002Fp>\n\n\u003Cp>The United States Food and Drug Administration (FDA) conducted an inspection of your firm, Fenwal International, Inc. (a Fresenius Kabi company), located at Road 357, Km 0.8, Maricao, PR 00606, between September 12, 2022 and September 24, 2022. During the inspection, the FDA investigators documented significant deviations from current good manufacturing practice (CGMP) requirements in the manufacture of your blood-pack units (BPUs) with and without in-line leukoreduction filters, as well as Alyx component solutions, Amicus component solutions, and InterSol, a platelet additive solution (collectively, “your products” or “your terminally sterilized products”)\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>. These deviations from CGMP requirements include failure to conform to applicable requirements of Section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) [21 U.S.C. § 351(a)(2)(B)] and Title 21, Code of Federal Regulations (21 CFR), Parts 210 and 211.\u003C\u002Fp>\n\n\u003Cp>At the close of the inspection, FDA issued and discussed with your firm a Form FDA-483, List of Inspectional Observations, which described significant deviations from CGMP requirements noted during the inspection. FDA identified additional significant deviations upon further review of the information collected during the September 2022 inspection, as discussed below. The CGMP deviations include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>1. Failure to follow established, approved written procedures and thoroughly investigate any unexplained discrepancy or the failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed [21 CFR 211.192]. Specifically:\u003C\u002Fp>\n\n\u003Cp>a. During the annual product review periods ranging from January 01, 2021 to February 28, 2022, approximately 28 batches\u002Flots of your terminally sterilized products exceeded your firm’s action limit for bioburden samples taken from bulk solutions (i.e., “mixing tanks”) or “finished unsterilized units.” Results for approximately 21 lots were considered too numerous to count (TNTC). Additionally, approximately 31 lots of finished unsterilized units exceeded the spore count action limit. At the time of the inspection, your investigations into these excursions were not thorough because the investigations did not include an evaluation to determine the root cause, although batches had been released.\u003C\u002Fp>\n\n\u003Cp>b. Your firm does not investigate “swarming organisms” as a TNTC result, as required by your established, written \u003Cem>Procedure for Plate Counting of Microbiological Samples\u003C\u002Fem> applicable to bioburden testing, water testing, and environmental monitoring among other tests.\u003C\u002Fp>\n\n\u003Cp>Your firm’s failure to conduct adequate failure investigations is a repeat deficiency noted during our 2010, 2012, 2013 and 2021 inspections.\u003C\u002Fp>\n\n\u003Cp>2. Failure to test in-process materials for identity, strength, quality, and purity, as appropriate, and approve or reject by the quality control unit, during the production process [21 CFR 211.110(c)]. For example, your firm failed to reject lots of your bulk solutions (i.e., “mixing tanks”) and finished unsterilized units with in-process bioburden results of TNTC.\u003C\u002Fp>\n\n\u003Cp>3. Failure to establish and follow appropriate written procedures designed to prevent microbiological contamination of drug products purporting to be sterile, including procedures for validation of all aseptic and sterilization processes [21 CFR 211.113(b)]. For example:\u003C\u002Fp>\n\n\u003Cp>a. Your firm has failed to establish that your sterilization process can achieve your established minimum sterility assurance level (SAL) of \u003Cstrong>(b)(4)\u003C\u002Fstrong> when TNTC bioburden levels are present in your finished unsterilized units.\u003C\u002Fp>\n\n\u003Cp>b. Your firm has failed to establish and follow appropriate written procedures to prevent microbiological contamination of finished units of your products prior to terminal sterilization. Bioburden control is critical for preventing a challenge to your validated sterilization process and to minimize bioburden-associated byproducts.\u003C\u002Fp>\n\n\u003Cp>4. Failure to clean, maintain, and, as appropriate for the nature of the drug, sanitize and\u002For sterilize equipment and utensils at appropriate intervals to prevent contamination that would alter the safety, identity, strength, quality, or purity of the drug product beyond the official or other established requirements [21 CFR 211.67(a)]. For example:\u003C\u002Fp>\n\n\u003Cp>a. Inspection of filling module \u003Cstrong>(b)(4)\u003C\u002Fstrong> on September 13, 2022, revealed an approximate two-inch hole on top of the HEPA box, broken edges and residue on the diffusion grate above the filling nozzles, tubing ports with missing tubing connections, and brown residue on filling equipment surfaces near the filling nozzle. This filling area is used to manufacture Amicus component solutions, Alyx component solutions, and Intersol.\u003C\u002Fp>\n\n\u003Cp>b. Inspection of mixing room \u003Cstrong>(b)(4)\u003C\u002Fstrong> on September 22, 2022, revealed apparent black growth on room-supply HEPA filters and black residue inside mixing tank \u003Cstrong>(b)(4)\u003Csup>\u003Cem>2\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>5. Failure to maintain buildings used in the manufacture, processing, packing, or holding of drug products in a good state of repair [21 CFR 211.58]. For example, FDA’s inspection of mixing room \u003Cstrong>(b)(4)\u003C\u002Fstrong> revealed gaps in the ceiling that connect to the unclassified utility space, cracked and peeling surfaces on the floors and walls, flaking paint on the ceiling near air return vents, and a tarp collecting pooling water in the ceiling space approximately fifty feet from filling room \u003Cstrong>(b)(4)\u003C\u002Fstrong>. It is essential that your facility is in a good state of repair to protect drug products from potential routes of contamination.\u003C\u002Fp>\n\n\u003Cp>6. Failure to establish laboratory controls that include scientifically sound and appropriate specifications, standards, and test procedures designed to assure that components, in-process material, and drug products conform to appropriate standards of identity, strength, quality, and purity [21 CFR 211.160(b)]. For example:\u003C\u002Fp>\n\n\u003Cp>a. Your approach to calculating the SAL for lots of finished unsterilized units of your products with TNTC pre-sterilization bioburden results is not scientifically sound. Your firm calculated the SAL using a value of \u003Cstrong>(b)(4)\u003C\u002Fstrong> when the results obtained were TNTC. As noted by your firm during the inspection, TNTC is not a number and cannot be used to calculate the SAL. Your firm has used this erroneous calculation to determine the impact of TNTC results on the sterility assurance of the involved lots.\u003C\u002Fp>\n\n\u003Cp>b. You did not conduct a study to demonstrate the suitability of your bioburden test method for Anticoagulant Citrate Dextrose Solution, USP, Formula A (ACD-A) that demonstrates your ability to detect a variety of organisms in the presence of ACD-A. Your bacteriostatic study, performed in 1988, only included \u003Cem>Bacillus subtilis\u003C\u002Fem> and \u003Cem>Candida Albicans\u003C\u002Fem> as test organisms. ACD-A is one of your Alyx and Amicus component solutions.\u003C\u002Fp>\n\n\u003Cp>c. During the inspection, our investigator observed microbial growth over the majority of the test plate and around the perimeter with no defined edges for bioburden tank sample 71643 for Citrate Phosphate Dextrose (CPD) bulk solution. Your Quality Manager stated that the observed plate growth would only be documented as 1 CFU. CPD is part of your BPU product.\u003C\u002Fp>\n\n\u003Cp>We acknowledge receipt of your letters dated October 17, 2022, November 14, 2022, December 16, 2022, January 19, 2023, February 14, 2023, March 17, 2023, April 17, 2023, May 12, 2023, and July 25, 2023, which respond to the Form FDA-483 and set forth your corrective actions. We have reviewed your represented corrective actions. For some of your corrective actions, you have not provided sufficient detail to assess their adequacy. For example, your firm has not provided sufficient evidence that corrective actions to reduce bioburden in mixing tanks and filled units are effective. More notably, your commitments do not adequately resolve your recurring violations, including your firm’s failure to conduct adequate failure investigations.\u003C\u002Fp>\n\n\u003Cp>Your firm, including your quality unit, continuously has failed to adequately correct your violations and—for those violations that FDA has observed during previous inspections—prevent their recurrence. Indeed, the nature of your violations demonstrates that your quality control unit has failed to ensure that your firm manufactures drug products that meet established specifications for identity, strength, quality, and purity.\u003C\u002Fp>\n\n\u003Cp>Additionally, the CGMP deviations cited in this letter pose a significant risk that the products may be contaminated with microorganisms. We note that organisms previously recovered in your facility and bioburden samples of your products were genetically matched to isolates from clinical cases of septic reactions involving \u003Cem>Acinetobacter\u003C\u002Fem> species and \u003Cem>Staphylococcus saprophyticus\u003C\u002Fem>\u003Csup>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>. In addition, an instance of TNTC in bioburden testing occurred in Amicus lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>, which was used to collect platelets implicated in a septic transfusion reaction. More recently, according to your April 2023 response, \u003Cem>Acinetobacter baumanni\u003C\u002Fem> was recovered from a tank used for Amicus lot \u003Cstrong>(b)(4)\u003C\u002Fstrong> on March 24, 2023, and an environmental monitoring sample on November 01, 2022.\u003C\u002Fp>\n\n\u003Cp>Neither this letter nor the observations noted on the Form FDA-483, which were discussed with you at the conclusion of the inspection, are intended to be an all-inclusive list of deficiencies that may be associated with your products. It is your responsibility to ensure that your establishment fully complies with the FD&amp;C Act, the Public Health Service Act (PHS Act), and all applicable regulations. You should take prompt action to correct these violations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address them.\u003C\u002Fp>\n\n\u003Cp>Failure to adequately correct these matters may lead to regulatory action without further notice. Such actions include seizure and\u002For injunction.\u003C\u002Fp>\n\n\u003Cp>We request that you respond in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to address any violations and prevent their recurrence. Include any documentation necessary to show that the matters have been addressed. If you do not believe your products are in violation of the FD&amp;C Act, PHS Act, or applicable regulations, include your reasoning and any supporting information for our consideration. If you cannot address these matters completely within fifteen (15) working days, please explain the reason for your delay and the timeframe for completion.\u003C\u002Fp>\n\n\u003Cp>Your response should be sent to Colleen Aspinwall, Compliance Officer; Valerie Grecek-Trinh, Compliance Officer; or LT Yvesna Blaise, Compliance Officer, at the following email addresses: Colleen.Aspinwall@fda.hhs.gov, Valerie.grecektrinh@fda.hhs.gov or Yvesna.blaise@fda.hhs.gov. If you have any questions, please contact Ms. Aspinwall at (561) 416-1065, ext. 1105, Ms. Grecek-Trinh at (904) 353-4560 ext. 118 or LT Blaise at (240) 381-4722, or via e-mail.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>(b)(7)(C)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003Cbr>\nMichael W. Roosevelt\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Biological Products Operations – Division 1\u003C\u002Fp>\n\n\u003Cp>Cc: Alvin Peralta Faulkner\u003Cbr>\nPlant Manager\u003Cbr>\nFenwal International, Inc.\u003Cbr>\nRoad 357, Km 0.8\u003Cbr>\nMaricao, PR 00606\u003C\u002Fp>\n\n\u003Cp>______________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Your products undergo \u003Cstrong>(b)(4)\u003C\u002Fstrong> in lieu of sterility testing.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> According to your correspondence to the Form FDA-483 dated October 17, 2022, the residue on six of \u003Cstrong>(b)(4)\u003C\u002Fstrong> HEPA filters was identified as mold and the residue in the tank was identified as inorganic carbon and stainless steel following sampling performed by your firm.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> FDA issued a communication regarding septic infusion reactions from apheresis platelets contaminated with Acinetobacter species and certain other bacterial species on April 16, 2019 and updated on December 2, 2021. The latest update, published on December 22, 2022, is available at https:\u002F\u002Fwww.fda.gov\u002Fvaccines-blood-biologics\u002Fsafety-availability-biologics\u002Fimportant-information-blood-establishments-and-transfusion-services-regarding-bacterial-0.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE SIGNATURE REQUIRED\n\nReference #:\n\n23-657085\n\nProduct:\n\nBiologics\n\nRecipient:\n\nRecipient Name\n\nDr. Christian Hauer\n\nRecipient Title\n\nPresident of Transfusion Medicine and Cell Therapies, MedTech Division\n\nFresenius Kabi AG\n\nElse-Kröner-Straße 1\n\n61352 Bad Homburg\n\nGermany\n\nIssuing Office:\n\nDivision of Biological Products Operations I\n\nUnited States\n\nWARNING LETTER\n\nSeptember 14, 2023\n\n23-657085\n\nDear Dr. Hauer:\n\nThe United States Food and Drug Administration (FDA) conducted an inspection of your firm, Fenwal International, Inc. (a Fresenius Kabi company), located at Road 357, Km 0.8, Maricao, PR 00606, between September 12, 2022 and September 24, 2022. During the inspection, the FDA investigators documented significant deviations from current good manufacturing practice (CGMP) requirements in the manufacture of your blood-pack units (BPUs) with and without in-line leukoreduction filters, as well as Alyx component solutions, Amicus component solutions, and InterSol, a platelet additive solution (collectively, “your products” or “your terminally sterilized products”)1. These deviations from CGMP requirements include failure to conform to applicable requirements of Section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) [21 U.S.C. § 351(a)(2)(B)] and Title 21, Code of Federal Regulations (21 CFR), Parts 210 and 211.\n\nAt the close of the inspection, FDA issued and discussed with your firm a Form FDA-483, List of Inspectional Observations, which described significant deviations from CGMP requirements noted during the inspection. FDA identified additional significant deviations upon further review of the information collected during the September 2022 inspection, as discussed below. The CGMP deviations include, but are not limited to, the following:\n\n1. Failure to follow established, approved written procedures and thoroughly investigate any unexplained discrepancy or the failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed [21 CFR 211.192]. Specifically:\n\na. During the annual product review periods ranging from January 01, 2021 to February 28, 2022, approximately 28 batches\u002Flots of your terminally sterilized products exceeded your firm’s action limit for bioburden samples taken from bulk solutions (i.e., “mixing tanks”) or “finished unsterilized units.” Results for approximately 21 lots were considered too numerous to count (TNTC). Additionally, approximately 31 lots of finished unsterilized units exceeded the spore count action limit. At the time of the inspection, your investigations into these excursions were not thorough because the investigations did not include an evaluation to determine the root cause, although batches had been released.\n\nb. Your firm does not investigate “swarming organisms” as a TNTC result, as required by your established, written Procedure for Plate Counting of Microbiological Samples applicable to bioburden testing, water testing, and environmental monitoring among other tests.\n\nYour firm’s failure to conduct adequate failure investigations is a repeat deficiency noted during our 2010, 2012, 2013 and 2021 inspections.\n\n2. Failure to test in-process materials for identity, strength, quality, and purity, as appropriate, and approve or reject by the quality control unit, during the production process [21 CFR 211.110(c)]. For example, your firm failed to reject lots of your bulk solutions (i.e., “mixing tanks”) and finished unsterilized units with in-process bioburden results of TNTC.\n\n3. Failure to establish and follow appropriate written procedures designed to prevent microbiological contamination of drug products purporting to be sterile, including procedures for validation of all aseptic and sterilization processes [21 CFR 211.113(b)]. For example:\n\na. Your firm has failed to establish that your sterilization process can achieve your established minimum sterility assurance level (SAL) of (b)(4) when TNTC bioburden levels are present in your finished unsterilized units.\n\nb. Your firm has failed to establish and follow appropriate written procedures to prevent microbiological contamination of finished units of your products prior to terminal sterilization. Bioburden control is critical for preventing a challenge to your validated sterilization process and to minimize bioburden-associated byproducts.\n\n4. Failure to clean, maintain, and, as appropriate for the nature of the drug, sanitize and\u002For sterilize equipment and utensils at appropriate intervals to prevent contamination that would alter the safety, identity, strength, quality, or purity of the drug product beyond the official or other established requirements [21 CFR 211.67(a)]. For example:\n\na. Inspection of filling module (b)(4) on September 13, 2022, revealed an approximate two-inch hole on top of the HEPA box, broken edges and residue on the diffusion grate above the filling nozzles, tubing ports with missing tubing connections, and brown residue on filling equipment surfaces near the filling nozzle. This filling area is used to manufacture Amicus component solutions, Alyx component solutions, and Intersol.\n\nb. Inspection of mixing room (b)(4) on September 22, 2022, revealed apparent black growth on room-supply HEPA filters and black residue inside mixing tank (b)(4)2.\n\n5. Failure to maintain buildings used in the manufacture, processing, packing, or holding of drug products in a good state of repair [21 CFR 211.58]. For example, FDA’s inspection of mixing room (b)(4) revealed gaps in the ceiling that connect to the unclassified utility space, cracked and peeling surfaces on the floors and walls, flaking paint on the ceiling near air return vents, and a tarp collecting pooling water in the ceiling space approximately fifty feet from filling room (b)(4). It is essential that your facility is in a good state of repair to protect drug products from potential routes of contamination.\n\n6. Failure to establish laboratory controls that include scientifically sound and appropriate specifications, standards, and test procedures designed to assure that components, in-process material, and drug products conform to appropriate standards of identity, strength, quality, and purity [21 CFR 211.160(b)]. For example:\n\na. Your approach to calculating the SAL for lots of finished unsterilized units of your products with TNTC pre-sterilization bioburden results is not scientifically sound. Your firm calculated the SAL using a value of (b)(4) when the results obtained were TNTC. As noted by your firm during the inspection, TNTC is not a number and cannot be used to calculate the SAL. Your firm has used this erroneous calculation to determine the impact of TNTC results on the sterility assurance of the involved lots.\n\nb. You did not conduct a study to demonstrate the suitability of your bioburden test method for Anticoagulant Citrate Dextrose Solution, USP, Formula A (ACD-A) that demonstrates your ability to detect a variety of organisms in the presence of ACD-A. Your bacteriostatic study, performed in 1988, only included Bacillus subtilis and Candida Albicans as test organisms. ACD-A is one of your Alyx and Amicus component solutions.\n\nc. During the inspection, our investigator observed microbial growth over the majority of the test plate and around the perimeter with no defined edges for bioburden tank sample 71643 for Citrate Phosphate Dextrose (CPD) bulk solution. Your Quality Manager stated that the observed plate growth would only be documented as 1 CFU. CPD is part of your BPU product.\n\nWe acknowledge receipt of your letters dated October 17, 2022, November 14, 2022, December 16, 2022, January 19, 2023, February 14, 2023, March 17, 2023, April 17, 2023, May 12, 2023, and July 25, 2023, which respond to the Form FDA-483 and set forth your corrective actions. We have reviewed your represented corrective actions. For some of your corrective actions, you have not provided sufficient detail to assess their adequacy. For example, your firm has not provided sufficient evidence that corrective actions to reduce bioburden in mixing tanks and filled units are effective. More notably, your commitments do not adequately resolve your recurring violations, including your firm’s failure to conduct adequate failure investigations.\n\nYour firm, including your quality unit, continuously has failed to adequately correct your violations and—for those violations that FDA has observed during previous inspections—prevent their recurrence. Indeed, the nature of your violations demonstrates that your quality control unit has failed to ensure that your firm manufactures drug products that meet established specifications for identity, strength, quality, and purity.\n\nAdditionally, the CGMP deviations cited in this letter pose a significant risk that the products may be contaminated with microorganisms. We note that organisms previously recovered in your facility and bioburden samples of your products were genetically matched to isolates from clinical cases of septic reactions involving Acinetobacter species and Staphylococcus saprophyticus3. In addition, an instance of TNTC in bioburden testing occurred in Amicus lot (b)(4), which was used to collect platelets implicated in a septic transfusion reaction. More recently, according to your April 2023 response, Acinetobacter baumanni was recovered from a tank used for Amicus lot (b)(4) on March 24, 2023, and an environmental monitoring sample on November 01, 2022.\n\nNeither this letter nor the observations noted on the Form FDA-483, which were discussed with you at the conclusion of the inspection, are intended to be an all-inclusive list of deficiencies that may be associated with your products. It is your responsibility to ensure that your establishment fully complies with the FD&C Act, the Public Health Service Act (PHS Act), and all applicable regulations. You should take prompt action to correct these violations.\n\nThis letter notifies you of our findings and provides you an opportunity to address them.\n\nFailure to adequately correct these matters may lead to regulatory action without further notice. Such actions include seizure and\u002For injunction.\n\nWe request that you respond in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to address any violations and prevent their recurrence. Include any documentation necessary to show that the matters have been addressed. If you do not believe your products are in violation of the FD&C Act, PHS Act, or applicable regulations, include your reasoning and any supporting information for our consideration. If you cannot address these matters completely within fifteen (15) working days, please explain the reason for your delay and the timeframe for completion.\n\nYour response should be sent to Colleen Aspinwall, Compliance Officer; Valerie Grecek-Trinh, Compliance Officer; or LT Yvesna Blaise, Compliance Officer, at the following email addresses: Colleen.Aspinwall@fda.hhs.gov, Valerie.grecektrinh@fda.hhs.gov or Yvesna.blaise@fda.hhs.gov. If you have any questions, please contact Ms. Aspinwall at (561) 416-1065, ext. 1105, Ms. Grecek-Trinh at (904) 353-4560 ext. 118 or LT Blaise at (240) 381-4722, or via e-mail.\n\n(b)(7)(C)\n\nSincerely,\n\n\u002FS\u002F\n\nMichael W. Roosevelt\n\nProgram Division Director\n\nOffice of Biological Products Operations – Division 1\n\nCc: Alvin Peralta Faulkner\n\nPlant Manager\n\nFenwal International, Inc.\n\nRoad 357, Km 0.8\n\nMaricao, PR 00606\n\n______________________\n\n1 Your products undergo (b)(4) in lieu of sterility testing.\n\n2 According to your correspondence to the Form FDA-483 dated October 17, 2022, the residue on six of (b)(4) HEPA filters was identified as mold and the residue in the tank was identified as inorganic carbon and stainless steel following sampling performed by your firm.\n\n3 FDA issued a communication regarding septic infusion reactions from apheresis platelets contaminated with Acinetobacter species and certain other bacterial species on April 16, 2019 and updated on December 2, 2021. The latest update, published on December 22, 2022, is available at https:\u002F\u002Fwww.fda.gov\u002Fvaccines-blood-biologics\u002Fsafety-availability-biologics\u002Fimportant-information-blood-establishments-and-transfusion-services-regarding-bacterial-0.","fresenius-kabi-ag-657085-09142023","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ffresenius-kabi-ag-657085-09142023","2026-10-26T08:08:43.325006+00:00","2023-09-29","657085","Biologics","Division of Biological Products Operations I","Dr. Christian Hauer","2026-08-20T00:37:55.679+00:00","VIA UNITED PARCEL SERVICE SIGNATURE REQUIRED","23-657085","2023-09-14",{"id":79,"raw":80,"subject":12,"body_html":84,"body_text":85,"firm_name":86,"letter_id":87,"created_at":88,"fei_number":19,"letter_url":89,"updated_at":90,"action_type":22,"case_status":23,"posted_date":91,"marcs_cms_no":92,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":93,"body_fetched_at":94,"delivery_method":95,"recipient_title":19,"reference_number":96,"action_taken_date":97,"medical_device_id":19,"response_letter_date":19},21643,[81,82,83,11,12,13,13,13],"\u003Ctime datetime=\"2026-09-01T04:00:00Z\">09\u002F01\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-08-25T04:00:00Z\">08\u002F25\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ffresenius-medical-care-ag-co-kgaa-730319-08252026\">Fresenius Medical Care AG &amp; Co. KGaA\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email Return Receipt Requested\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-26-119\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Ms. Helen Giza\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Fresenius Medical Care AG &amp; Co. KGaA\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>Else-Kröner-Straße 1\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>61352\u003C\u002Fspan> \u003Cspan>Bad Homburg v.d. Höhe\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Germany\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:(b)(4)\"> (b)(4)\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-26-119\u003C\u002Fp>\u003Cp>August 25, 2026\u003C\u002Fp>\u003Cp>Dear Ms. Giza:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, Fresenius USA Manufacturing, Inc. dba Fresenius Medical Care North America Ogden Plant, FEI 1713747, at 475 W. 13th St., Ogden, Utah, from March 2 to 6, 2026.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>We reviewed your March 27, 2026, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\u003C\u002Fp>\u003Cp>During our inspection, our investigator observed specific violations including, but not limited to, the following.\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You failed to adequately investigate customer complaints for the large volume parenteral (LVP) bag drug products you manufacture. Your investigations were not thorough and did not appropriately evaluate the risk to product quality. You also failed to identify and implement adequate and timely corrective actions and preventive actions (CAPAs).\u003C\u002Fp>\u003Cp>Specifically, in August 2025 you initiated an investigation due to a complaint trend for leaking bags of Delflex Peritoneal Dialysis Solution. This investigation noted that you eventually received 35 complaints covering approximately 156 bags from multiple batches. Your investigation attributed the bag leaks “to holes caused by printing.”\u003C\u002Fp>\u003Cp>Despite your Risk Management Matrix indicating peritonitis as a potential harm and recommending the highest severity level, you instead assigned the lowest severity level with the potential harm being “damage of property.” Although you ultimately conducted a recall in April 2026 after our inspection, you chose not to conduct a recall following the results of your August 2025 investigation.\u003C\u002Fp>\u003Cp>Your justifications for these decisions included: the lack of attributable peritonitis cases, product labeling instructed users to inspect bags for leaks, the leaks should be readily detected before treatment, and leaking fluid should collect in the overwrap.\u003C\u002Fp>\u003Cp>Notably, following our inspection, you state that you reexamined part of one batch and “found presence of perforations in the primary container without substantial fluid present in the overwrap,” demonstrating your error in assuming that users can consistently detect leaks. Moreover, users should not be relied upon to detect leaking bags. In addition, once you knew of the trend of leaking bags in marketed product, there should have been a commensurate increase in urgency to contain the issue.\u003C\u002Fp>\u003Cp>Your decision not to recall these batches at that time exposed peritoneal dialysis (PD) patients to potentially non-sterile drug products. The use of non-sterile PD solution elevates the risk of developing peritonitis, the clinical consequences of which may include serious and potentially life-threatening complications. In addition, a significant component in this drug, dextrose, could serve as a nutritional source for contaminating microorganisms and promote their growth.\u003C\u002Fp>\u003Cp>In your response, you acknowledge that the risk assessment should have been based on peritonitis risk, and you should not have assumed that users would detect any leaking unit. Your firm reassessed the risk for this incident and decided to recall the impacted lots. You also revised your procedure to assure that known and potential harms are evaluated during risk assessments.\u003C\u002Fp>\u003Cp>Your response is inadequate. It does not include a sufficient CAPA, including improving detection of leaking units during manufacturing to prevent their release and distribution. This is especially concerning considering the numerous complaints, Field Alert Reports, and recalled batches in the last three years for leaking LVP bags manufactured at your facility. Notably, two Field Alert Reports you previously submitted involved leaking LVP bags with microbial contamination.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive, independent assessment of the root causes of leaking bags including, but not limited to:\u003Cbr>o A failure mode analysis for the potential causes of leaking bags that addresses the deficiencies in the printing technology used by your firm, as well as any other potential causes associated with handling of bags by equipment and personnel\u003Cbr>o An independent review of your printing controls and their capabilities, including potential for contributing to leaking bags\u003Cbr>o An analysis of alternative printing technologies that can minimize or eliminate the printing step as a cause of leaking bags\u003Cbr>o CAPA to address the identified root causes of leaking bags, such as the replacement of the current printing technology\u003C\u002Fli>\u003Cli>A comprehensive assessment and remediation plan to ensure your quality unit (QU) is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003Cbr>o A determination of whether procedures used by your firm are robust and appropriate\u003Cbr>o Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices\u003Cbr>o A complete and final review of each batch and its related information before the QU disposition decision\u003Cbr>o Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products\u003C\u002Fli>\u003Cli>A comprehensive assessment of your overall system for investigating deviations, discrepancies, complaints, out-of-specification results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, quality unit oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\u003C\u002Fli>\u003Cli>An independent review of in-process criteria for major and critical defects, including but not limited to leakers. Perform a retrospective evaluation, including:\u003Cbr>o A list of the number and types of all defects\u003Cbr>o Detailed long-term summaries (i.e., at least 5 years) of batch performance that address the period of recurring leaking incidents\u003Cbr>o All instances of batches with atypically high defects rates, with potential root cause of these deviations\u003C\u002Fli>\u003Cli>Provide a comprehensive process capability assessment of your manufacturing process, with special emphasis on the capability of critical operational steps including but not limited to the detection of leaking bags, and any related CAPA to be initiated in response to the capability assessment. Also, include an assessment of operator handling practices and machine stresses that could lead to loss of bag integrity.\u003C\u002Fli>\u003Cli>Provide a remediated program that provides for ongoing statistical assessment of processing line performance to vigilantly monitor state of control. Specifically, include your program for statistical process control of each batch of drug products manufactured by your firm to monitor intra-batch and inter-batch variation and promptly detect a drift in process control.\u003C\u002Fli>\u003Cli>Provide the protocol for and subsequent report from an independent review of the qualification report(s), validation report(s), and maintenance program for the equipment that forms, fills, and seals your drug product bags. Also include an independent review of the methods used to detect leaking bags throughout processing, the frequency of monitoring, and the validation report for each method.\u003C\u002Fli>\u003Cli>A detailed summary of your validation program for ensuring a state of control throughout the product lifecycle, along with associated procedures. Describe your program for process performance qualification, and ongoing vigilant monitoring of both intra-batch and inter-batch variation to ensure a continuing state of control. Also, describe your equipment and facility qualification program.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>2. Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your visual inspection program was inadequate to ensure that sterile injectable drug products were essentially free of visible particulates. Specifically, you failed to appropriately qualify personnel who performed visual inspections of injectable products. Your visual inspection qualification kit did not include adequately representative visible particulates (e.g., size), and your qualification records lacked sufficient detail to determine the qualifications of staff who perform visual inspection of \u003Cstrong>(b)(4)\u003C\u002Fstrong> bags.\u003C\u002Fp>\u003Cp>Your response states that your visual inspection qualification kit contained representative particulates. You add that you are developing a new kit that will continue to contain such particles, and that you will periodically review production and post market data to verify the kit remains representative.\u003C\u002Fp>\u003Cp>Your response is inadequate. It does not address the failure of your visual inspection qualification program to demonstrate that visual inspection personnel can detect visible particles at a level that meets the appropriate standard. The example particles in your kit may not be representative of smaller particles in your drug products.\u003C\u002Fp>\u003Cp>Visual detection of particulates is a probabilistic process that depends on, among other things, ensuring that visible particulates can be reproducibly detected by trained personnel with appropriate visual acuity. Your qualification kit should contain particles of a size and composition that adequately challenge inspectors across the range of particulate sizes that may be present in your drug product and should be qualified to demonstrate that inspectors can reliably detect visible particulates relevant to your specific product and container\u002Fclosure system. These qualification kits should typically contain particles in the range of 100-150 microns to adequately challenge inspector detection capabilities.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A remediation plan that better assures ongoing management oversight throughout the manufacturing lifecycle of all drug products. Provide a more data-driven and scientifically sound program that identifies sources of process variability, and assures that manufacturing operations meet appropriate parameters and quality standards. This includes, but is not limited to, evaluating suitability of equipment for its intended use, ensuring quality of input materials, determining the capability and reliability of each manufacturing process step and its controls, and vigilant ongoing monitoring of process performance and product quality.\u003C\u002Fli>\u003Cli>A comprehensive, independent assessment and remediation plan for your visual inspection program to ensure compliance with CGMP. The remediation plan should include but not be limited to:\u003Cbr>o Improved visual inspection methods, as appropriate\u003Cbr>o Improved qualification protocols and associated records for all staff performing visual inspection\u003Cbr>o Incorporation of U.S. Pharmacopeia (USP) &lt;790&gt; Visible Particulates in Injections standards into your procedures\u003Cbr>o Use of an appropriate range of visible particulate types and sizes, including particles of also approximately 100-150 microns, as part of staff qualification studies\u003Cbr>o All other provisions necessary to ensure appropriate qualification of visual particulate inspectors\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>Drug Recall\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>On April 6, 2026, you issued voluntary recalls of DELFLEX Dextrose Peritoneal Dialysis Solution due to Lack of Assurance of Sterility. The company announcements were posted to the FDA website:\u003Cbr>https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fires\u002Findex.cfm?Product=219904\u003Cbr>https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fires\u002Findex.cfm?Product=219905\u003C\u002Fp>\u003Cp>\u003Cstrong>CGMP Consultant\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive six-system audit\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> of your entire operation for CGMP compliance and evaluate the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\u003Cp>If you are considering an action that is likely to lead to a disruption in the supply of drugs produced at your facility, FDA requests that you contact CDER’s Drug Shortages Staff immediately, at drugshortages@fda.hhs.gov, so that FDA can work with you on the most effective way to bring your operations into compliance with the law. Contacting the Drug\u003C\u002Fp>\u003Cp>Shortages Staff also allows you to meet any obligations you may have to report discontinuances or interruptions in your drug manufacture under 21 U.S.C. 356C(b). This also allows FDA to consider, as soon as possible, what actions, if any, may be needed to avoid shortages and protect the health of patients who depend on your products.\u003C\u002Fp>\u003Cp>Correct any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\u003Cp>Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 1713747 and ATTN: Russell Riley.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\u003Cp>CC: Mr. Brett A. Barton\u003Cbr>General Manager\u003Cbr>Vice President of Manufacturing Operations Ogden Plant\u003Cbr>Fresenius USA Manufacturing, Inc. dba Fresenius Medical Care North America Ogden Plant\u003Cbr>Email: \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>________________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Under program enhancements for the Generic Drug User Fee Amendments (GDUFA) reauthorization for fiscal years (FYs) 2023-2027, also known as the GDUFA III Commitment Letter, your facility may be eligible for a Post-Warning Letter Meeting to obtain preliminary feedback from FDA on the adequacy and completeness of your corrective action plans.\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email Return Receipt Requested\n\nReference #:\n\n320-26-119\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMs. Helen Giza\n\nRecipient Title\n\nChief Executive Officer\n\nFresenius Medical Care AG & Co. KGaA\n\nElse-Kröner-Straße 1\n\n61352 Bad Homburg v.d. Höhe\n\nGermany\n\n(b)(4)\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWarning Letter 320-26-119\nAugust 25, 2026\nDear Ms. Giza:\nThe United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, Fresenius USA Manufacturing, Inc. dba Fresenius Medical Care North America Ogden Plant, FEI 1713747, at 475 W. 13th St., Ogden, Utah, from March 2 to 6, 2026.\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\nWe reviewed your March 27, 2026, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\nDuring our inspection, our investigator observed specific violations including, but not limited to, the following.\n1. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\nYou failed to adequately investigate customer complaints for the large volume parenteral (LVP) bag drug products you manufacture. Your investigations were not thorough and did not appropriately evaluate the risk to product quality. You also failed to identify and implement adequate and timely corrective actions and preventive actions (CAPAs).\nSpecifically, in August 2025 you initiated an investigation due to a complaint trend for leaking bags of Delflex Peritoneal Dialysis Solution. This investigation noted that you eventually received 35 complaints covering approximately 156 bags from multiple batches. Your investigation attributed the bag leaks “to holes caused by printing.”\nDespite your Risk Management Matrix indicating peritonitis as a potential harm and recommending the highest severity level, you instead assigned the lowest severity level with the potential harm being “damage of property.” Although you ultimately conducted a recall in April 2026 after our inspection, you chose not to conduct a recall following the results of your August 2025 investigation.\nYour justifications for these decisions included: the lack of attributable peritonitis cases, product labeling instructed users to inspect bags for leaks, the leaks should be readily detected before treatment, and leaking fluid should collect in the overwrap.\nNotably, following our inspection, you state that you reexamined part of one batch and “found presence of perforations in the primary container without substantial fluid present in the overwrap,” demonstrating your error in assuming that users can consistently detect leaks. Moreover, users should not be relied upon to detect leaking bags. In addition, once you knew of the trend of leaking bags in marketed product, there should have been a commensurate increase in urgency to contain the issue.\nYour decision not to recall these batches at that time exposed peritoneal dialysis (PD) patients to potentially non-sterile drug products. The use of non-sterile PD solution elevates the risk of developing peritonitis, the clinical consequences of which may include serious and potentially life-threatening complications. In addition, a significant component in this drug, dextrose, could serve as a nutritional source for contaminating microorganisms and promote their growth.\nIn your response, you acknowledge that the risk assessment should have been based on peritonitis risk, and you should not have assumed that users would detect any leaking unit. Your firm reassessed the risk for this incident and decided to recall the impacted lots. You also revised your procedure to assure that known and potential harms are evaluated during risk assessments.\nYour response is inadequate. It does not include a sufficient CAPA, including improving detection of leaking units during manufacturing to prevent their release and distribution. This is especially concerning considering the numerous complaints, Field Alert Reports, and recalled batches in the last three years for leaking LVP bags manufactured at your facility. Notably, two Field Alert Reports you previously submitted involved leaking LVP bags with microbial contamination.\nIn response to this letter, provide:\nA comprehensive, independent assessment of the root causes of leaking bags including, but not limited to:\no A failure mode analysis for the potential causes of leaking bags that addresses the deficiencies in the printing technology used by your firm, as well as any other potential causes associated with handling of bags by equipment and personnel\no An independent review of your printing controls and their capabilities, including potential for contributing to leaking bags\no An analysis of alternative printing technologies that can minimize or eliminate the printing step as a cause of leaking bags\no CAPA to address the identified root causes of leaking bags, such as the replacement of the current printing technology\nA comprehensive assessment and remediation plan to ensure your quality unit (QU) is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\no A determination of whether procedures used by your firm are robust and appropriate\no Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices\no A complete and final review of each batch and its related information before the QU disposition decision\no Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products\nA comprehensive assessment of your overall system for investigating deviations, discrepancies, complaints, out-of-specification results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, quality unit oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\nAn independent review of in-process criteria for major and critical defects, including but not limited to leakers. Perform a retrospective evaluation, including:\no A list of the number and types of all defects\no Detailed long-term summaries (i.e., at least 5 years) of batch performance that address the period of recurring leaking incidents\no All instances of batches with atypically high defects rates, with potential root cause of these deviations\nProvide a comprehensive process capability assessment of your manufacturing process, with special emphasis on the capability of critical operational steps including but not limited to the detection of leaking bags, and any related CAPA to be initiated in response to the capability assessment. Also, include an assessment of operator handling practices and machine stresses that could lead to loss of bag integrity.\nProvide a remediated program that provides for ongoing statistical assessment of processing line performance to vigilantly monitor state of control. Specifically, include your program for statistical process control of each batch of drug products manufactured by your firm to monitor intra-batch and inter-batch variation and promptly detect a drift in process control.\nProvide the protocol for and subsequent report from an independent review of the qualification report(s), validation report(s), and maintenance program for the equipment that forms, fills, and seals your drug product bags. Also include an independent review of the methods used to detect leaking bags throughout processing, the frequency of monitoring, and the validation report for each method.\nA detailed summary of your validation program for ensuring a state of control throughout the product lifecycle, along with associated procedures. Describe your program for process performance qualification, and ongoing vigilant monitoring of both intra-batch and inter-batch variation to ensure a continuing state of control. Also, describe your equipment and facility qualification program.\n2. Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\nYour visual inspection program was inadequate to ensure that sterile injectable drug products were essentially free of visible particulates. Specifically, you failed to appropriately qualify personnel who performed visual inspections of injectable products. Your visual inspection qualification kit did not include adequately representative visible particulates (e.g., size), and your qualification records lacked sufficient detail to determine the qualifications of staff who perform visual inspection of (b)(4) bags.\nYour response states that your visual inspection qualification kit contained representative particulates. You add that you are developing a new kit that will continue to contain such particles, and that you will periodically review production and post market data to verify the kit remains representative.\nYour response is inadequate. It does not address the failure of your visual inspection qualification program to demonstrate that visual inspection personnel can detect visible particles at a level that meets the appropriate standard. The example particles in your kit may not be representative of smaller particles in your drug products.\nVisual detection of particulates is a probabilistic process that depends on, among other things, ensuring that visible particulates can be reproducibly detected by trained personnel with appropriate visual acuity. Your qualification kit should contain particles of a size and composition that adequately challenge inspectors across the range of particulate sizes that may be present in your drug product and should be qualified to demonstrate that inspectors can reliably detect visible particulates relevant to your specific product and container\u002Fclosure system. These qualification kits should typically contain particles in the range of 100-150 microns to adequately challenge inspector detection capabilities.\nIn response to this letter, provide:\nA remediation plan that better assures ongoing management oversight throughout the manufacturing lifecycle of all drug products. Provide a more data-driven and scientifically sound program that identifies sources of process variability, and assures that manufacturing operations meet appropriate parameters and quality standards. This includes, but is not limited to, evaluating suitability of equipment for its intended use, ensuring quality of input materials, determining the capability and reliability of each manufacturing process step and its controls, and vigilant ongoing monitoring of process performance and product quality.\nA comprehensive, independent assessment and remediation plan for your visual inspection program to ensure compliance with CGMP. The remediation plan should include but not be limited to:\no Improved visual inspection methods, as appropriate\no Improved qualification protocols and associated records for all staff performing visual inspection\no Incorporation of U.S. Pharmacopeia (USP) \u003C790> Visible Particulates in Injections standards into your procedures\no Use of an appropriate range of visible particulate types and sizes, including particles of also approximately 100-150 microns, as part of staff qualification studies\no All other provisions necessary to ensure appropriate qualification of visual particulate inspectors\nDrug Recall\nOn April 6, 2026, you issued voluntary recalls of DELFLEX Dextrose Peritoneal Dialysis Solution due to Lack of Assurance of Sterility. The company announcements were posted to the FDA website:\nhttps:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fires\u002Findex.cfm?Product=219904\nhttps:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fires\u002Findex.cfm?Product=219905\nCGMP Consultant\nBased upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive six-system audit1 of your entire operation for CGMP compliance and evaluate the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA.\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\nIf you are considering an action that is likely to lead to a disruption in the supply of drugs produced at your facility, FDA requests that you contact CDER’s Drug Shortages Staff immediately, at drugshortages@fda.hhs.gov, so that FDA can work with you on the most effective way to bring your operations into compliance with the law. Contacting the Drug\nShortages Staff also allows you to meet any obligations you may have to report discontinuances or interruptions in your drug manufacture under 21 U.S.C. 356C(b). This also allows FDA to consider, as soon as possible, what actions, if any, may be needed to avoid shortages and protect the health of patients who depend on your products.\nCorrect any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\nFailure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days1. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 1713747 and ATTN: Russell Riley.\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research\nCC: Mr. Brett A. Barton\nGeneral Manager\nVice President of Manufacturing Operations Ogden Plant\nFresenius USA Manufacturing, Inc. dba Fresenius Medical Care North America Ogden Plant\nEmail: (b)(4)\n________________________\n1 Under program enhancements for the Generic Drug User Fee Amendments (GDUFA) reauthorization for fiscal years (FYs) 2023-2027, also known as the GDUFA III Commitment Letter, your facility may be eligible for a Post-Warning Letter Meeting to obtain preliminary feedback from FDA on the adequacy and completeness of your corrective action plans.","Fresenius Medical Care AG & Co. KGaA","fresenius-medical-care-ag-co-kgaa-730319-08252026","2026-09-07T05:14:13.57002+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ffresenius-medical-care-ag-co-kgaa-730319-08252026","2026-10-26T08:08:43.502309+00:00","2026-09-01","730319","Ms. Helen Giza","2026-09-07T05:14:22.608+00:00","Via Email Return Receipt Requested","320-26-119","2026-08-25",{"id":99,"raw":100,"subject":40,"body_html":104,"body_text":105,"firm_name":86,"letter_id":106,"created_at":45,"fei_number":19,"letter_url":107,"updated_at":108,"action_type":22,"case_status":23,"posted_date":109,"marcs_cms_no":110,"product_type":50,"closeout_date":19,"issuing_office":38,"recipient_name":111,"body_fetched_at":112,"delivery_method":113,"recipient_title":19,"reference_number":19,"action_taken_date":114,"medical_device_id":19,"response_letter_date":19},1690,[101,102,103,38,40,13,13,13],"\u003Ctime datetime=\"2023-12-19T14:20:00Z\">12\u002F19\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-12-04T05:00:00Z\">12\u002F04\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ffresenius-medical-care-ag-co-kgaa-666791-12042023\">Fresenius Medical Care AG &amp; Co. KGaA\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>United Parcel Service\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Helen Giza\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Fresenius Medical Care AG &amp; Co. KGaA\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>Else-Kröner-Straße 1\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Bad Homburg v.d.\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>61352\u003C\u002Fspan> \u003Cspan>Höhe\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Germany\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n  \u003Cdiv>\n    \u003Cdiv>Secondary Issuing Offices\u003C\u002Fdiv>\n          \u003Cdiv>\n              \u003Cdiv>    \u003Cbr>\n    \n     \n        \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n    \n    \n    \n    \n\u003C\u002Fdiv>\n              \u003C\u002Fdiv>\n      \u003C\u002Fdiv>\n\n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003Cbr>\nCMS # 666791\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>December 4, 2023\u003Cbr>\n\u003Cbr>\nDear Ms. Giza:\u003C\u002Fp>\n\n\u003Cp>The United States Food and Drug Administration (FDA) conducted an inspection of your firm’s medical device operations, Fresenius Medical Care Holdings, Inc. (Fresenius), d.b.a. Fresenius Care North America, located at 920 Winter Street, Building 920, Waltham, MA 02451-1521, from June 26, 2023, through August 2, 2023. During the inspection, FDA investigators determined that your firm is a medical device specification developer responsible for complaint handling, recall management, and quality system oversite of your North American manufacturing of dialysis systems and accessories, such as the 2008 Series Hemodialysis Machine. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003C\u002Fp>\n\n\u003Cp>This inspection revealed that the above devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820, and Title 21 CFR Part 806, Medical Devices, Reports of Corrections and Removals.\u003C\u002Fp>\n\n\u003Cp>We received your responses dated August 24, 2023, and September 22, 2023, from Kathleen Storro, Vice President, Quality Management System, North America, which responded to the Form FDA 483, List of Inspectional Observations issued to your firm on August 2, 2023. We address your responses below.\u003C\u002Fp>\n\n\u003Cp>Violations include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>1. Failure to establish and maintain procedures for implementing corrective and preventive actions, as required by 820.100(a). Specifically, your Corrective Action and Preventive Action, Procedure No. S100016-03, Rev E. Dated January 30, 2023, is inadequate in that:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>You did not take a corrective and preventative action until almost 2-years after you learned of a potential issue impacting your Hemodialysis Machines that contain peroxide crosslinked silicone tubing. You were notified on December 3, 2020, of PCB emissions that were detected from the peroxide crosslinked silicone tubing component, and you did not open CAPA 1100660 until June 15, 2022. The devices were not recalled until November 25, 2022.\u003C\u002Fli>\n\t\u003Cli>You failed to adequately investigate the potential health impact of PCB related compounds leaching from the components of your 2008 K, 2008 K2 and 2008 T Hemodialysis Machines that use peroxide crosslinked silicone tubing. The risk calculation you performed to determine the risk level of PCB related compounds leaching was inadequate to determine the overall risk of the device. You did not include the minimum body weight of 20 kg, as listed in the instructions for use (IFU) when calculating the Health Hazard Assessment (HHA-FA-2022-19-W) for the 2008 series of Hemodialysis Machines with peroxide crosslinked silicone tubing.\u003C\u002Fli>\n\t\u003Cli>You failed to verify the corrective actions were effective for CAPA 932073, as required by your CAPA procedure. CAPA 932073 resulted in a recall of the 2008T and 2008T Bluestar Hemodialysis Machine with CDX-Indicated for acute and chronic dialysis therapy due the false alarm \"Remove USB 2 Device\" (RES 91154).\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>We reviewed your firm’s responses and have concluded that the adequacy of your response cannot be determined at this time because you have not completed your proposed corrective and preventive actions. Please provide an update on the status of your corrective actions.\u003C\u002Fp>\n\n\u003Cp>2. Failure to document all activities and their results required under this section (Corrective and preventive action) as required by 21 CFR 820.100(b). Specifically:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>CAPA 1100660 dated June 15, 2022, opened for the PCB related compounds issue failed to adequately document all the activities you performed after you became aware of PCB related compounds finding. The CAPA states that there are no actions required however you had action plans for PCB related compounds which you implemented via design change, product hold and a rework which were covered by NCs 1145819 and 1150080 and Quality Event 1057552. Your CAPA also failed to document your first awareness of PCB related compounds finding in peroxide crosslinked silicone which you received from your supplier. As well as corrections to distributed devices, which you initiated on November 25, 2022, to update\u002Fcorrect the silicone tubing.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>We reviewed your firm’s responses and have concluded that the adequacy of your response cannot be determined at this time because you have not completed your proposed corrective and preventive actions. Please provide an update on the status of your corrective actions.\u003C\u002Fp>\n\n\u003Cp>3. Failure to establish and maintain procedures for validating the device design, as required by 21 CFR 820.30(g). Specifically, Design Validation Procedure, S100021-13, was not followed when conducting retrospective design validation of your 2008T, 2008 K and 2008 K2 Hemodialysis Machines to determine if the devices can be used safely and effectively by the intended users. \u003Cstrong>(b)(4)\u003C\u002Fstrong> rounds of real-world studies were conducted to detect PCB related compounds, and if detected, determine which day of use the PCBs were detected. For example:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Failure to establish the protocols for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> rounds of studies and for round&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> failed to adequately establish the protocol.\u003C\u002Fli>\n\t\u003Cli>The test method was not specific regarding background blank dialysate usage to repeating the test.\u003C\u002Fli>\n\t\u003Cli>The round \u003Cstrong>(b)(4)\u003C\u002Fstrong> study, initial results found PCB related compounds present after 60 days of usage; however, the device was later identified as never have been used.\u003C\u002Fli>\n\t\u003Cli>Samples were collected for \u003Cstrong>(b)(4)\u003C\u002Fstrong> for the study; however, the protocol identifies samples were to be collected for \u003Cstrong>(b)(4)\u003C\u002Fstrong> only. You failed to update the protocol when they made changes.\u003C\u002Fli>\n\t\u003Cli>Failure to approve the protocol before performing the formal validation.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>We reviewed your firm’s responses and have concluded that the adequacy of your response cannot be determined at this time because you have not completed your proposed corrective and preventive actions. Please provide an update on the status of your corrective actions.\u003C\u002Fp>\n\n\u003Cp>Exposure to PCBs can have long-term health consequences linked to hepatic effects (including serum hepatic enzyme elevation), dermal changes (acne, rashes), certain cancer (e.g., liver, gallbladder, biliary tract, gastrointestinal tract, brain, malignant melanoma, non-Hodgkin’s lymphoma), neurodevelopmental and behavioral toxicity via lactational exposure, endocrine dysfunction (thyroid), neurobehavioral alterations, immune system alterations, anemia, and male reproductive effects. Additionally, patients with end stage renal disease on dialysis are vulnerable and adverse events may get magnified or present differently in this population due to their altered physiology.\u003C\u002Fp>\n\n\u003Cp>Our inspection also revealed that your firm’s hemodialysis machines are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 806 – Medical Devices; Reports of Corrections and Removals. Significant violations include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>4. A correction or removal, conducted to reduce a risk to health posed by a device, was not reported in writing to FDA within 10-working days of initiating such correction or removal, as required by 21 CFR 806.10(b). Specifically, to reduce a risk to health posed by the device, you initiated a field action starting on November 25, 2022, for your 2008 Hemodialysis Machines by going to customers’ sites to change the silicone tubing associated with PCBA related compounds leaching. As of the time of the recent inspection, you have updated \u003Cstrong>(b)(4)\u003C\u002Fstrong> Hemodialysis Machines with a new silicone tubing “platinum cross linked silicon” without a formal notice to FDA. You field corrected the devices after FDA published a safety communication on potential risk of exposure to toxic compounds when using certain hemodialysis machines manufactured by Fresenius Medical Care.\u003C\u002Fp>\n\n\u003Cp>Our office confirms receipt of your letter, dated September 6, 2023, Report of Corrections and Removal (RES 92788). We reviewed your firm’s responses and have concluded that the adequacy of your response cannot be determined at this time. Your responses state that CAPA 1472083 has been opened and root cause investigation, appropriate process improvements to S100036-01, Coordinating Field Corrections, Removals, or Recalls, will be implemented, as necessary. Please provide an update on the status of this CAPA.\u003C\u002Fp>\n\n\u003Cp>Your firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\n\n\u003Cp>Other federal agencies may take your compliance with the Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\u003C\u002Fp>\n\n\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed.\u003C\u002Fp>\n\n\u003Cp>Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\n\n\u003Cp>Your firm’s response should be sent to: Gina Brackett, Director of Compliance Branch, at oradevices1firmresponse@fda.hhs.gov. Refer to CMS # 666791 when replying. If you have any questions about the contents of this letter, please contact Compliance Officer, Richard\u003Cbr>\nCherry at 215-717-3075 or at richard.cherry@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Joseph Matrisciano, Jr.\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Medical Device and Radiological\u003Cbr>\nHealth Division 1\u003C\u002Fp>\n\n\u003Cp>\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Courtney H. Lias, Ph.D.\u003Cbr>\nDirector\u003Cbr>\nOHT3: Office of GastroRenal, ObGyn, General\u003Cbr>\nHospital and Urology Devices Office of\u003Cbr>\nProduct Evaluation and Quality Center for\u003Cbr>\nDevices and Radiological Health\u003C\u002Fp>\n\n\u003Cp>cc: Linda J. Jalbert, Senior Vice President, Medical Safety and Postmarket Systems\u003Cbr>\nFresenius Medical Care Holdings, Inc.\u003Cbr>\n920 Winter Street, Bld. 920\u003Cbr>\nWaltham, MA 02451-1521\u003Cbr>\n(UPS overnight delivery)\u003C\u002Fp>\n\n\u003Cp>Kathleen Storro, Vice President Quality Management System, North America\u003Cbr>\nFresenius Medical Care Holdings, Inc.\u003Cbr>\n920 Winter Street, Bld. 920\u003Cbr>\nWaltham, MA 02451-1521\u003Cbr>\n(UPS overnight delivery)\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nUnited Parcel Service\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nHelen Giza\n\nRecipient Title\n\nCEO\n\nFresenius Medical Care AG & Co. KGaA\n\nElse-Kröner-Straße 1\n\nBad Homburg v.d.\n\n61352 Höhe\n\nGermany\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nSecondary Issuing Offices\n\nUnited States\n\nWARNING LETTER\n\nCMS # 666791\n\nDecember 4, 2023\n\nDear Ms. Giza:\n\nThe United States Food and Drug Administration (FDA) conducted an inspection of your firm’s medical device operations, Fresenius Medical Care Holdings, Inc. (Fresenius), d.b.a. Fresenius Care North America, located at 920 Winter Street, Building 920, Waltham, MA 02451-1521, from June 26, 2023, through August 2, 2023. During the inspection, FDA investigators determined that your firm is a medical device specification developer responsible for complaint handling, recall management, and quality system oversite of your North American manufacturing of dialysis systems and accessories, such as the 2008 Series Hemodialysis Machine. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\n\nThis inspection revealed that the above devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820, and Title 21 CFR Part 806, Medical Devices, Reports of Corrections and Removals.\n\nWe received your responses dated August 24, 2023, and September 22, 2023, from Kathleen Storro, Vice President, Quality Management System, North America, which responded to the Form FDA 483, List of Inspectional Observations issued to your firm on August 2, 2023. We address your responses below.\n\nViolations include, but are not limited to, the following:\n\n1. Failure to establish and maintain procedures for implementing corrective and preventive actions, as required by 820.100(a). Specifically, your Corrective Action and Preventive Action, Procedure No. S100016-03, Rev E. Dated January 30, 2023, is inadequate in that:\n\nYou did not take a corrective and preventative action until almost 2-years after you learned of a potential issue impacting your Hemodialysis Machines that contain peroxide crosslinked silicone tubing. You were notified on December 3, 2020, of PCB emissions that were detected from the peroxide crosslinked silicone tubing component, and you did not open CAPA 1100660 until June 15, 2022. The devices were not recalled until November 25, 2022.\n\nYou failed to adequately investigate the potential health impact of PCB related compounds leaching from the components of your 2008 K, 2008 K2 and 2008 T Hemodialysis Machines that use peroxide crosslinked silicone tubing. The risk calculation you performed to determine the risk level of PCB related compounds leaching was inadequate to determine the overall risk of the device. You did not include the minimum body weight of 20 kg, as listed in the instructions for use (IFU) when calculating the Health Hazard Assessment (HHA-FA-2022-19-W) for the 2008 series of Hemodialysis Machines with peroxide crosslinked silicone tubing.\n\nYou failed to verify the corrective actions were effective for CAPA 932073, as required by your CAPA procedure. CAPA 932073 resulted in a recall of the 2008T and 2008T Bluestar Hemodialysis Machine with CDX-Indicated for acute and chronic dialysis therapy due the false alarm \"Remove USB 2 Device\" (RES 91154).\n\nWe reviewed your firm’s responses and have concluded that the adequacy of your response cannot be determined at this time because you have not completed your proposed corrective and preventive actions. Please provide an update on the status of your corrective actions.\n\n2. Failure to document all activities and their results required under this section (Corrective and preventive action) as required by 21 CFR 820.100(b). Specifically:\n\nCAPA 1100660 dated June 15, 2022, opened for the PCB related compounds issue failed to adequately document all the activities you performed after you became aware of PCB related compounds finding. The CAPA states that there are no actions required however you had action plans for PCB related compounds which you implemented via design change, product hold and a rework which were covered by NCs 1145819 and 1150080 and Quality Event 1057552. Your CAPA also failed to document your first awareness of PCB related compounds finding in peroxide crosslinked silicone which you received from your supplier. As well as corrections to distributed devices, which you initiated on November 25, 2022, to update\u002Fcorrect the silicone tubing.\n\nWe reviewed your firm’s responses and have concluded that the adequacy of your response cannot be determined at this time because you have not completed your proposed corrective and preventive actions. Please provide an update on the status of your corrective actions.\n\n3. Failure to establish and maintain procedures for validating the device design, as required by 21 CFR 820.30(g). Specifically, Design Validation Procedure, S100021-13, was not followed when conducting retrospective design validation of your 2008T, 2008 K and 2008 K2 Hemodialysis Machines to determine if the devices can be used safely and effectively by the intended users. (b)(4) rounds of real-world studies were conducted to detect PCB related compounds, and if detected, determine which day of use the PCBs were detected. For example:\n\nFailure to establish the protocols for the (b)(4) rounds of studies and for round (b)(4) failed to adequately establish the protocol.\n\nThe test method was not specific regarding background blank dialysate usage to repeating the test.\n\nThe round (b)(4) study, initial results found PCB related compounds present after 60 days of usage; however, the device was later identified as never have been used.\n\nSamples were collected for (b)(4) for the study; however, the protocol identifies samples were to be collected for (b)(4) only. You failed to update the protocol when they made changes.\n\nFailure to approve the protocol before performing the formal validation.\n\nWe reviewed your firm’s responses and have concluded that the adequacy of your response cannot be determined at this time because you have not completed your proposed corrective and preventive actions. Please provide an update on the status of your corrective actions.\n\nExposure to PCBs can have long-term health consequences linked to hepatic effects (including serum hepatic enzyme elevation), dermal changes (acne, rashes), certain cancer (e.g., liver, gallbladder, biliary tract, gastrointestinal tract, brain, malignant melanoma, non-Hodgkin’s lymphoma), neurodevelopmental and behavioral toxicity via lactational exposure, endocrine dysfunction (thyroid), neurobehavioral alterations, immune system alterations, anemia, and male reproductive effects. Additionally, patients with end stage renal disease on dialysis are vulnerable and adverse events may get magnified or present differently in this population due to their altered physiology.\n\nOur inspection also revealed that your firm’s hemodialysis machines are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 806 – Medical Devices; Reports of Corrections and Removals. Significant violations include, but are not limited to, the following:\n\n4. A correction or removal, conducted to reduce a risk to health posed by a device, was not reported in writing to FDA within 10-working days of initiating such correction or removal, as required by 21 CFR 806.10(b). Specifically, to reduce a risk to health posed by the device, you initiated a field action starting on November 25, 2022, for your 2008 Hemodialysis Machines by going to customers’ sites to change the silicone tubing associated with PCBA related compounds leaching. As of the time of the recent inspection, you have updated (b)(4) Hemodialysis Machines with a new silicone tubing “platinum cross linked silicon” without a formal notice to FDA. You field corrected the devices after FDA published a safety communication on potential risk of exposure to toxic compounds when using certain hemodialysis machines manufactured by Fresenius Medical Care.\n\nOur office confirms receipt of your letter, dated September 6, 2023, Report of Corrections and Removal (RES 92788). We reviewed your firm’s responses and have concluded that the adequacy of your response cannot be determined at this time. Your responses state that CAPA 1472083 has been opened and root cause investigation, appropriate process improvements to S100036-01, Coordinating Field Corrections, Removals, or Recalls, will be implemented, as necessary. Please provide an update on the status of this CAPA.\n\nYour firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\n\nOther federal agencies may take your compliance with the Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\n\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed.\n\nYour firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration as part of your response.\n\nYour firm’s response should be sent to: Gina Brackett, Director of Compliance Branch, at oradevices1firmresponse@fda.hhs.gov. Refer to CMS # 666791 when replying. If you have any questions about the contents of this letter, please contact Compliance Officer, Richard\n\nCherry at 215-717-3075 or at richard.cherry@fda.hhs.gov.\n\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\n\nSincerely,\n\n\u002FS\u002F\n\nJoseph Matrisciano, Jr.\n\nProgram Division Director\n\nOffice of Medical Device and Radiological\n\nHealth Division 1\n\n\u002FS\u002F\n\nCourtney H. Lias, Ph.D.\n\nDirector\n\nOHT3: Office of GastroRenal, ObGyn, General\n\nHospital and Urology Devices Office of\n\nProduct Evaluation and Quality Center for\n\nDevices and Radiological Health\n\ncc: Linda J. Jalbert, Senior Vice President, Medical Safety and Postmarket Systems\n\nFresenius Medical Care Holdings, Inc.\n\n920 Winter Street, Bld. 920\n\nWaltham, MA 02451-1521\n\n(UPS overnight delivery)\n\nKathleen Storro, Vice President Quality Management System, North America\n\nFresenius Medical Care Holdings, Inc.\n\n920 Winter Street, Bld. 920\n\nWaltham, MA 02451-1521\n\n(UPS overnight delivery)","fresenius-medical-care-ag-co-kgaa-666791-12042023","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ffresenius-medical-care-ag-co-kgaa-666791-12042023","2026-10-26T08:08:43.457936+00:00","2023-12-19","666791","Helen Giza","2026-08-20T00:26:00.628+00:00","United Parcel Service","2023-12-04",5,{"510k":117,"classification":118,"enforcement":119,"event":120,"event_backfill":121,"pma":122,"warning_letter":123},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-17T04:00:34.414+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]